

**NOVEL 2-SACCHARINYLMETHYL AND
4,5,6,7-TETRAHYDRO-2-SACCHARINYLMETHYL
PHOSPHATES, PHOSPHONATES AND PHOSPHINATES
USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND
COMPOSITIONS AND METHOD OF USE THEREOF**

This invention relates to novel 2-saccharinyl-
methyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl
phosphates, phosphonates and phosphinates which inhibit the
enzymatic activity of proteolytic enzymes, to compositions
5 containing the same, to the method of use thereof in the
treatment of degenerative diseases and to processes for their
preparation.

The inhibition of proteolytic enzymes by nontoxic
reagents is useful in the treatment of degenerative disorders,
10 such as emphysema, rheumatoid arthritis and pancreatitis, in
which proteolysis is a substantive element. Protease inhibitors
are widely utilized in biomedical research. Serine proteases
are the most widely distributed class of proteolytic enzymes.
Some serine proteases are characterized as chymotrypsin-like
15 or elastase-like based upon their substrate specificity.

Chymotrypsin and chymotrypsin-like enzymes
normally cleave peptide bonds in proteins at a site at which
the amino acid residue on the carboxyl side is typically Trp,
Tyr, Phe, Met, Leu or another amino acid residue which
20 contains aromatic or large alkyl side chains. Elastase and
elastase-like enzymes normally cleave peptide bonds at a site
at which the amino acid residue on the carboxyl side of the
bond is typically Ala, Val, Ser, Leu or other similar, smaller
amino acids. Both chymotrypsin-like and elastase-like
25 enzymes are found in leukocytes, mast cells and pancreatic
juice in higher organisms, and are secreted by many types of
bacteria, yeast and parasites.

This Sheet Has Been Replaced



Japanese Patent Publication 72/00419, discloses a number of 2-saccharinylmethyl benzoates, including 2-saccharinylmethyl benzoate per se and 2-saccharinylmethyl 2,4-dichlorobenzoate and 4-nitrobenzoate. The compounds are
5 said to have strong activity against rice blast, rice sheath blight, rice helminthosporium leaf spot and rice bacterial leaf blight disease.

Sunkel et al., J. Med. Chem., 31, 1886-1890 (1988) disclose a series of 2-saccharinyl-lower-alkyl-1,4-dihydro-
10 pyridine-3-carboxylates having platelet aggregation inhibitory and anti-thrombotic activities.

Chen U.S. Patent 4,263,393, discloses various 2-aroylemethyilsaccharins useful as photographic elements and film units.

15 Mulvey et al. U.S. Patent 4,195,023, discloses R_1 -2- R_2 CO-1,2-benzisothiazol-3-ones, where R_1 is halogen, alkoxy, alkylamino, dialkylamino, alkoxy-carbonyl, amino, nitro or hydrogen in the benzenoid ring and R_2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, halophenyl, heteroaryl or
20 substituted heteroaryl, and R_1 -2-A-CO saccharins, where R_1 has the same meanings as the benzenoid ring substituents in the 1,2-benzisothiazol-3-ones and A is alkyl, alkenyl, alkynyl, cycloalkyl, fluorophenyl, heteroaryl or substituted-heteroaryl. The compounds are said to have elastase
25 inhibitory activity and to be useful in the treatment of emphysema.

Zimmerman et al., J. Biol. Chem., 255 (20), 9848-9851 (1980) disclose N-acylsaccharins, where the acyl group is furoyl, thenoyl, benzoyl, cyclopropanoyl, ethylbutyryl
30 and acryloyl, having serine protease inhibitory activity.

Chemical Abstracts 81, 22249n (1974) discloses 4-methylphenyl 2-saccharinylcarboxylate which is said to have bactericidal and fungicidal activities.



Several classes of compounds are known to be serine protease inhibitors. For example Powers in U.S. Patent 4,659,855 discloses arylsulfonyl fluoride derivatives useful as elastase inhibitors. Doherty *et al.*

- 5 U.S. Patents 4,547,371 and 4,623,645 disclose cephalosporin sulfones and sulfoxides, respectively, which are stated to be potent elastase inhibitors useful in the treatment of inflammatory conditions, especially arthritis and emphysema.

- Teshima *et al.*, J. Biol. Chem., 257 (9), 5085-5091
10 (1982) report the results of studies on serine proteases (human leukocyte elastase, porcine pancreatic elastase, cathepsin G and bovine chymotrypsin A_α) with 4-nitrophenylesters and thioesters of N-trifluoroacetylanthranylates, 2-substituted-4H-3,1-benzoxazin-4-ones, 2-substituted-
15 4-quinazolinones and 2-substituted-4-chloroquinazolines.

- Cha, Biochem. Pharmacol., 24, 2177-2185 (1975) discusses kinetic approaches to the study of the binding of inhibitors to macromolecules, such as enzymes, and methods for determination of such parameters as the inhibition
20 constants, reaction rates and bound and unbound enzyme concentrations.

- Jones *et al.*, U.S. Patent 4,276,298 discloses 2-R-1,2-benzisothiazolinone-1,1-dioxides, where R is phenyl substituted by fluoro, dinitro, trifluoromethyl, cyano, alkoxy-carbonyl, alkylcarbonyl, carboxyl, carbamoyl, alkylacylamino,
25 alkylsulfonyl, N,N-dialkylsulfamoyl, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulfonyl and trifluoromethylsulfinyl, or pyridyl substituted the same as R when R is phenyl except that pyridyl may also be mono-nitro substituted. The
30 compounds are said to have protease enzyme inhibitory activity, especially elastase inhibitory activity, and to be useful in the treatment of emphysema, rheumatoid arthritis and other inflammatory diseases.

Powers et al., Biochem., 24, 2048-2058 (1985) discloses studies of the inhibitions of four chymotrypsin-like enzymes, cathepsin G, rat mast cell proteases I and II, human skin chymase and chymotrypsin A_α, by N-furoylsaccharin and N-(2,4-dicyanophenyl)saccharin.

Svoboda et al., Coll. Czech. Chem. Commun., 51, 1133-1139 (1986) disclose the preparation of 4-hydroxy-2H-1,2-benzothiazine-3-carboxylates by intramolecular Dieckmann condensation of 2H-1,2-benzisothiazol-3-one-2-acetate-1,1-dioxide esters.

Reczek et al., U.S. Patents 4,350,752 and 4,363,865 and Vanmeter et al., U.S. Patent 4,410,618 relate to photographic reagents (Reczek 4,350,752 and Vanmeter et al.) and photographic dyes (Reczek 4,363,865) and disclose various 2-substituted-saccharins useful for such applications, for example photographic reagents bound through a heteroatom to an imidomethyl blocking group (Reczek 4,350,752), carrier-diffusible photographic dyes bound to the nitrogen atom of an imide through a 1,1-alkylene group (Reczek 4,363,865) and N-acylmethylimides which are described as blocked photographic reagents and which have a residue of an organic photographic reagent containing a hetero atom through which it is bound to the blocking group (Vannmeter).

Freed et al., U.S. Patent 3,314,960 discloses 2-(1,1,3-trioxo-1,2-benzisothiazol-2-yl)glutarimides which are stated to be useful as sedatives.

2-Chloromethylsaccharin is disclosed in French Patent 1,451,417 as an intermediate for the preparation of N-methylsaccharin d,l-trans-chrysanthemate, useful as an insecticide, and Lo U.S. Patent 3,002,884 discloses 2-chloro, 2-bromo and 2-iodomethylsaccharins, useful as fungicidal agents.



Dunlap et al. PCT application WO 90/13549,
discloses a series of 2-substituted saccharin derivatives useful
as proteolytic enzyme inhibitors.

The present invention relates to 4-R₁-R₂-R₃-
5 2-saccharinylmethyl, 4-R₄-4-R₅-6-R₆-4,5,6,7-tetrahydro-
2-saccharinylmethyl and 4,7-C-4,5,6,7-tetrahydro-
2-saccharinylmethyl phosphates, phosphonates and
phosphinates of formulae I, II and IIA respectively
hereinbelow which have protease enzyme inhibitory activity
10 and which are useful in the treatment of degenerative
diseases.


The invention also relates to compositions for the
treatment of degenerative diseases which comprise a
pharmaceutical carrier and an effective proteolytic enzyme
15 inhibiting amount of a compound of formula I, II or IIA.

The invention further relates to a method of use of
a compound of formula I, II or IIA in the treatment of
degenerative diseases which comprises administering to a
patient in need of such treatment a medicament containing an
20 effective proteolytic enzyme inhibiting amount of the
compound of formula I, II or IIA.


The invention also relates to a process for the
preparation of a compound of formula I, II or IIA which
comprises reacting a 4-R₁-R₂-R₃-2-halomethylsaccharin, a
25 4-R₄-4-R₅-6-R₆-4,5,6,7-tetrahydro-2-halomethylsaccharin or a
4,7-C-4,5,6,7-tetrahydro-2-halomethylsaccharin with a
phosphate, phosphonate or phosphinic acid of formula III
hereinbelow in the presence of an acid-acceptor.

More specifically this invention relates to
30 4-R₁-R₂-R₃-2-saccharinylmethyl and 4-R₄-4-R₅-6-R₆-
4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates,
phosphonates and phosphinates having the formulae:





I



II

wherein:


5 R₁ is hydrogen, halogen, lower-alkyl, perfluoro-lower-alkyl, perchloro-lower-alkyl, lower-alkenyl, lower-alkynyl, cyano, amino, lower-alkylamino, di-lower-alkylamino, carboxamido, lower-alkoxy, benzyloxy, hydroxy, lower-alkoxy-carbonyl or phenyl;

R₂ and R₃ are independently hydrogen or a substituent in any of the available 5-, 6- or 7-positions selected from the group consisting of halogen, cyano, nitro, N=B, 1-lower-alkyl-2-pyrrolyl, lower-alkylsulfonylamino, polyfluoro-lower-alkylsulfonylamino, polychloro-lower-alkylsulfonylamino, aminosulfonyl, lower-alkyl, polyfluoro-lower-alkyl, polychloro-lower-alkyl, cycloalkyl, lower-alkoxy, hydroxy, carboxy, carboxamido, hydroxy-lower-alkyl, formyl, aminomethyl, polyfluoro-lower-alkylsulfonyl, polychloro-lower-alkylsulfonyl, lower-alkylsulfonylaminosulfonyl, lower-



- alkoxycarbonyl-lower-alkylamino, lower-alkylcarbonylamino, lower-alkoxy-poly-lower-alkyleneoxy, cycloalkyloxy, hydroxy-lower-alkoxy, polyhydroxyalkoxy, or acetal or ketal thereof, polyalkoxyalkoxy, (lower-alkoxy)₂P(O)O-, -SR, -SOR, 5 -SO₂R, -OCOR, -O-(C₁₋₁₀-alkylene)-COOR, -O-(C₁₋₁₀-alkylene)-COOH and -O-(C₂₋₁₀-alkylene)-N=B, where R is lower-alkyl, phenyl, benzyl or naphthyl, or phenyl or naphthyl substituted by from one to two substituents selected from lower-alkyl, lower-alkoxy or halogen, and -N=B in each instance is amino, 10 lower-alkylamino, di-lower-alkylamino, 1-azetidiny, 1-pyrrolidiny, 1-piperidiny, 4-morpholiny, 1-piperaziny, 4-lower-alkyl-1-piperaziny, 4-benzyl-1-piperaziny, 1-imidazolyl or (carboxy-lower-alkyl)amino;
- or R₂ and R₃ together represent a 3-atom or 15 4-atom unsubstituted or methylated saturated bridge bridging the carbon atoms at the 5,6 or 6,7 positions, wherein the atoms of the bridge consist of one or two carbon atoms and two of the same or different heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;
- 20 R₄ is hydrogen, lower-alkyl or phenyl;
R₅ is hydrogen or primary lower-alkyl;
or R₄ and R₅, taken together, represent ethylene;
R₆ is hydrogen or lower-alkoxy;
m and n are independently 0 or 1;
- 25 when m and n are 1, A and B are independently hydrogen, lower-alkyl, phenyl, lower-alkoxyphenyl or benzyl, or, taken together, represent:






where R_7 and R_8 are independently hydrogen or chlorine,
 R_9 and R_{10} each is hydrogen or together represent iso-
 propylidene, p is 0 or 1 and r is 2, 3 or 4;

5 when m is 1 and n is 0, A and B are independently
 lower-alkyl, phenyl, benzyl or 2-pyridinyl; and

 when m and n are 0, A and B are independently
 lower-alkyl, phenyl or lower-alkoxyphenyl.

10 The invention also relates to compounds of the
 formula:



IIA



wherein C is methylene, ethylene or dimethylmethylene, preferably methylene, and A, B, m and n have the meaning defined hereinbefore for formulae I and II.

Preferred compounds of formula I are those

5 wherein:

R₁ is hydrogen, lower-alkyl, especially C₁₋₄ lower-alkyl and more especially propyl, isopropyl or sec-butyl, or lower-alkoxy, especially methoxy or ethoxy;

10 R₂ is lower-alkoxy, especially C₁₋₃ lower-alkoxy and more especially methoxy or isopropoxy, polyalkoxyalkoxy, especially 2,3-dimethoxypropoxy, lower-alkoxy-poly-lower-alkyleneoxy, especially methoxy-lower-alkyleneoxyethoxy, or polyhydroxyalkoxy, or ketal or acetal thereof, especially dihydroxyalkoxy, or ketal or acetal thereof, and more
15 especially 2,3-dihydroxypropoxy, or dimethyl ketal thereof;

R₃ is hydrogen or lower-alkoxy, especially methoxy;

m and n both are 0 or 1;

20 when m and n are 1, A and B are independently hydrogen, lower-alkyl, phenyl, lower-alkoxyphenyl or benzyl; and

when m and n are 0, A and B are independently lower-alkyl, phenyl or lower-alkoxyphenyl.


25 Other preferred compounds of formula I are those wherein:

R₁ is hydrogen, lower-alkyl, especially C₁₋₄ lower-alkyl and more especially isopropyl or sec-butyl, or lower-alkoxy, especially methoxy or ethoxy;

30 R₂ is hydrogen, hydroxy or lower-alkoxy, especially methoxy or ethoxy, or polyhydroxyalkoxy, or ketal or acetal thereof, especially dihydroxyalkoxy, or ketal or acetal thereof, more especially 2,3-dihydroxypropoxy, or dimethyl ketal thereof;

35 R₃ is hydrogen;
m and n both are 0 or 1;

This Sheet Has Been Replaced



when m and n are 1, A and B are independently, especially both, hydrogen, lower-alkyl, especially C₁₋₄ lower-alkyl and more especially methyl, ethyl, isopropyl or butyl, phenyl, lower-alkoxyphenyl or benzyl; and

5 when m and n are 0, A and B are independently, especially both, lower-alkyl, especially C₁₋₄ lower-alkyl and more especially butyl, phenyl or lower-alkoxyphenyl, especially methoxyphenyl and more especially 4-methoxyphenyl.

10 Preferred compounds of formula II are those wherein:

R₄ is hydrogen or lower-alkyl, especially methyl, ethyl or isopropyl, more especially methyl;

R₅ is hydrogen or methyl;

15 R₆ is hydrogen or lower-alkoxy;

m and n are both 0 or 1;

when m and n are 1, A and B are independently hydrogen, lower-alkyl, phenyl or benzyl; and

20 when m and n are 0, A and B are independently lower-alkyl, phenyl or lower-alkoxyphenyl.

Other preferred compounds of formula II are those wherein:

R₄ is lower-alkyl, especially methyl;

R₅ is primary lower-alkyl, especially methyl;

25 R₆ is hydrogen or lower-alkoxy, especially hydrogen;

m and n both are 0 or 1, especially 1;

A and B are independently, especially both, lower-alkyl, especially C₁₋₄ lower-alkyl.

30 Particularly preferred compounds of formula II are those wherein

R₄ is hydrogen or lower-alkyl; and

R₅ is hydrogen or primary lower-alkyl; or

R₄ and R₅, taken together, represent ethylene



It should be understood that the compounds having the general structural formulas I and II are usually named in the chemical literature as 1,2-benzisothiazol-3(2H)-one 1,1-dioxides. However for the sake of brevity, such compounds are frequently named as saccharin derivatives, and that nomenclature will be used hereinafter in describing the compounds of the invention and their biological properties.


As used herein the terms lower-alkyl, lower-alkoxy and lower-alkane mean monovalent aliphatic radicals, including branched chain radicals, of from one to ten carbon atoms. Thus the lower-alkyl (or lower-alkane) moiety of such groups include, for example, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, t-butyl, n-pentyl, 2-methyl-3-butyl, 1-methylbutyl, 2-methylbutyl, neopentyl, n-hexyl, 1-methylpentyl, 3-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 2-hexyl, 3-hexyl, 1,1,3,3-tetramethylpentyl, 1,1-dimethyloctyl and the like.

As used herein the terms cycloalkyl and cycloalkyloxy mean such radicals having from three to seven carbon atoms illustrated by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cycloheptyloxy.

As used herein the term halogen (or halo) means fluorine, chlorine, bromine or iodine.

As used herein the terms lower-alkenyl and lower-alkynyl mean monovalent, unsaturated radicals, including branched chain radicals, of from two to ten carbon atoms and thus include 1-ethenyl, 1-(2-propenyl), 1-(2-butenyl), 1-(1-methyl-2-propenyl), 1-(4-methyl-2-pentenyl), 4,4,6-trimethyl-2-heptenyl, 1-ethynyl, 1-(2-propynyl), 1-(2-butylnyl), 1-(1-methyl-2-propynyl), 1-(4-methyl-2-pentylnyl), and the like.

As used herein, the term C₂₋₁₀-alkylene means divalent, saturated radicals, including branched chain radicals, of from two to ten carbon atoms having their free valences on



different carbon atoms; and the term C₁₋₁₀-alkylene means
divalent, saturated radicals, including branched chain radicals,
of from one to ten carbon atoms having their free valences on
the same or different carbon atoms. Such terms thus include
5 1,2-ethylene, 1,3-propylene, 1,4-butylene, 1-methyl-
1,2-ethylene, 1,8-octylene and the like and in the case only of
C₁₋₁₀, also methylene, ethylidene, propylidene and the like.

As used herein, the term lower-alkoxy-poly-lower-
alkyleneoxy means such radicals in which lower-alkoxy has
10 the meaning given above, poly means 2 to 4, and lower-
alkylene in lower-alkyleneoxy means divalent saturated
radicals, including branched radicals, of from two to five
carbon atoms. That term thus includes CH₃(OCH₂CH₂)_pO-,
CH₃CH₂[OCH₂CH(CH₃)_pO-, where p = 2-4, and the like.

15 As used herein, hydroxy-lower-alkoxy means
lower-alkoxy as defined above substituted by a hydroxy group
other than on the C-1 carbon atom and thus includes
2-hydroxyethoxy and the like.

As used herein, the term polyhydroxyalkoxy
20 means such a group wherein alkoxy is a monovalent aliphatic
radical of from two to five carbon atoms substituted by from
two or four hydroxy groups none of which are attached to the
same or the C-1 carbon atom and thus includes 2,3-dihydroxy-
propoxy, 2,3,4,5-tetrahydroxypentoxy and the like.

25 As used herein, the term polyalkoxyalkoxy means
monovalent aliphatic alkoxy radicals of from three to five
carbon atoms substituted by from two to four methoxy or
ethoxy groups none of which are attached to the same or the
C-1 carbon atom.


30 The compounds of the present invention inhibit the
activity of serine proteases, specifically human leukocyte
elastase and the chymotrypsin-like enzymes, and are thus
useful in the treatment of degenerative disease conditions
such as emphysema, rheumatoid arthritis, pancreatitis, cystic
35 fibrosis, chronic bronchitis, adult respiratory distress



syndrome, inflammatory bowel disease, psoriasis, bullous pemphigous and alpha-1-antitrypsin deficiency.

The compounds of formulas I, II and IIA are prepared by reaction of a 4-R₁-R₂-R₃-2-halomethylsaccharin, 4-R₄-4-R₅-6-R₆-4,5,6,7-tetrahydro-2-halomethylsaccharin or 4,7-C-4,5,6,7-tetrahydro-2-halomethylsaccharin respectively with an appropriate phosphoric acid di-ester, phosphonic acid mono-ester or phosphinic acid of the formula

This Sheet Has Been Replaced




III

where A, B, m and n have the meanings given hereinabove except that when m and n are 1, A and B are other than hydrogen. The reaction can be carried out in the presence of an acid-acceptor, such as an alkali metal carbonate, a tri-lower-alkylamine or 1,8-diazabicyclo[5.4.0]undec-7-ene, hereinafter DBU. The reaction is carried out in an organic solvent inert under the conditions of the reaction, for example acetone, methylethylketone (MEK), acetonitrile, tetrahydrofuran (THF), diethylether, dimethylformamide (DMF), N-methylpyrrolidinone, methylene dichloride (MDC), xylene, toluene or lower-alkanols, at a temperature in the range from ambient up to the boiling point of the solvent used.

The compounds of formulas I, II and IIA wherein m and n are 1 and A and B are hydrogen are prepared by hydrogenolysis of the corresponding compounds wherein m and n are 1 and A and B are benzyl.

The 4-R₁-R₂-R₃-2-halomethylsaccharins required for the preparation of the compounds of formula I are prepared by the methods described by D'Alelio *et al.*,

J. Macromol. Sci-Chem., A3(5), 941 (1969) and Saari et al.,
J. Het. Chem., 23, 1253 (1986). In the method described by
Saari, a methyl ester of an appropriate anthranilic acid is
prepared by conventional means from the substituted
5 anthranilic acid and the ester diazotized. The diazonium salt is
then reacted with sulfur dioxide and cupric chloride to
produce a sulfonyl chloride which is then reacted with
concentrated ammonium hydroxide to produce the substituted
saccharin derivatives of formula IV. The latter, on reaction
10 with formaldehyde in a lower-alkanol solvent, affords the
4-R₁-R₂-R₃-2-hydroxy-methylsaccharins of formula V, which,
on reaction with a thionyl halide or a phosphorus trihalide,
afford the corresponding 4-R₁-R₂-R₃-2-halomethylsaccharin
derivatives of formula VI.
15 The 4-R₁-R₂-R₃-2-halomethylsaccharins of
formula VI, where R₁, R₂, R₃ have the meanings given above
and X is chlorine or bromine, can also be prepared by reaction
of a corresponding 4-R₁-R₂-R₃-2-phenylthiomethylsaccharin
with a sulfonyl halide in an inert organic solvent, for example
20 MDC, ethylene dichloride (EDC) or carbon tetrachloride, at a
temperature from around 0°C to around 30°C. The 4-R₁-R₂-R₃-
2-phenylthiomethylsaccharins are in turn prepared by
reaction of a 4-R₁-R₂-R₃-saccharin of formula IV with a halo-
methylphenyl sulfide in an inert organic solvent, such as
25 toluene, xylene, DMF or MDC at a temperature in the range
from ambient up to the boiling point of the solvent used. The
reaction can be carried out by reaction of the halomethyl
phenyl sulfide with either the thallium salt of the saccharin
derivative of formula IV (prepared by reaction of the
30 saccharin derivative with a thallium lower-alkoxide in a
lower-alkanol); or with a di-lower-alkyl ammonium salt of the
saccharin derivative (prepared as described below) in the
presence of a tetra-lower-alkyl ammonium halide, such as
tetrabutyl ammonium bromide (hereinafter TBAB); or with the
35 saccharin derivative of formula IV per se in the presence of a




tetra-lower-alkyl ammonium halide; or with the saccharin derivative of formula IV per se in the presence of a tetra-lower-alkyl ammonium halide and an alkali metal lower-alkoxide, such as potassium t-butoxide.

- 5 The saccharins of formula IV may also be converted to the chloromethyl saccharins of formula VI, wherein X is Cl, in one step by reaction with an excess of formaldehyde or a formaldehyde equivalent, such as paraformaldehyde or 1,3,5-trioxane, and a chlorosilane, 10 preferably chlorotrimethylsilane, in the presence of a Lewis acid, preferably a catalytic amount of stannic chloride, in an inert solvent, preferably 1,2-dichloroethane (ethylenedichloride, EDC).

- These approaches are illustrated as follows, where 15 R₁, R₂ and R₃ have the meanings given above, Alk is lower-alkyl, X is halogen and Ph is phenyl.


This Sheet Has Been Replaced





The compounds of formula IV can also be prepared by reaction of a 2-R₁-R₂-R₃-N,N-di-lower-alkylbenzamide of formula VII with one molar equivalent of a lower-alkyl alkali metal, such as lithium, optionally in the presence of a tetra-
5 lower-alkylethylenediamine in an inert organic solvent, for example THF, and reaction of the resulting alkali metal salt either with sulfur dioxide at a temperature in the range from -50°C to -80°C followed by reaction of the resulting alkali metal sulfinat with hydroxylamine-O-sulfonic acid in the
10 presence of aqueous base, or with a sulfonyl halide followed by ammonia. When the sulfur dioxide-hydroxylamine-O-sulfonic acid route is used, it is particularly advantageous to neutralize the hydroxylamine-O-sulfonic acid with a base, preferably with one equivalent of aqueous sodium hydroxide,
15 prior to addition of the alkali metal sulfinat. The resulting 2-R₁-R₂-R₃-6-amino-sulfonyl-N,N-di-lower-alkyl-benzamide is thereafter heated in an acid medium to effect cyclization of the latter to produce the di-lower-alkyl ammonium salt of the desired 2-R₁-R₂-R₃-saccharin of formula IV, which can be used
20 as such in the subsequent reaction or, if desired, can be hydrolyzed in dilute acid and the free saccharin isolated. It is preferred to carry out the cyclization in refluxing glacial acetic acid. The method is illustrated as follows where R₁, R₂, R₃ and Alk have the meanings given above, and the alkali metal is
25 lithium.






The compounds of formula IV where R_1 is either primary or secondary lower-alkyl, and which are useful as intermediates for the preparation of the compounds of formula I as described above, are prepared by one of the following methods.

The compounds of formula IV where R_1 is primary lower-alkyl are prepared by reacting a 4-methyl- R_2 - R_3 -saccharin (formula IV, R_1 is CH_3) with two molar equivalents of a lower-alkyl lithium in an inert organic solvent, for example THF, and reacting the resulting lithium salt with one molar equivalent of a lower-alkyl halide, both reactions being carried out at a temperature in the range from about -50°C to $+80^\circ\text{C}$.

The compounds of formula IV where R_1 is primary lower-alkyl and R_2 and R_3 are other than hydrogen, or R_1 is secondary lower-alkyl and R_2 and R_3 are as defined for formula I comprises reaction of a 2-primary-lower-alkyl- R_2 - R_3 -N,N-di-lower-alkylbenzamide (formula VII, R_1 is primary-lower-alkyl) with one molar equivalent of either lower-alkyl lithium in the presence of a tetra-lower-alkylethylenediamine or a lithium di-lower-alkylamide, optionally in the presence of a tetra-lower-alkylethylenediamine, in an inert organic solvent, for example THF, and reaction of the resulting lithium salt with one molar equivalent

This Sheet Has Been Replaced




of a lower-alkyl halide at a temperature in the range from about -50°C to -80°C . The resulting 2-primary or secondary-lower-alkyl- $\text{R}_2\text{-R}_3\text{-N,N-di-lower-alkyl-benzamide}$ is thereafter converted to the compounds of formula IV, where


- 5 R_1 is primary or secondary lower-alkyl, by the same sequence of reactions described above, i.e., by reaction of the 2-primary or secondary-lower-alkyl- $\text{R}_2\text{-R}_3\text{-N,N-di-lower-alkylbenzamide}$ with one molar equivalent of a lower-alkyl lithium; reaction of
10 the resulting lithium salt either with sulfur dioxide followed by hydroxylamine-O-sulfonic acid in the presence of base or with a sulfonyl halide followed by ammonia; and cyclization of the product to the desired 4-primary or secondary-lower-alkyl- $\text{R}_2\text{-R}_3\text{-saccharin}$ of formula IV.

- When the 2-lower-alkyl group in the 2-lower-
15 alkyl- $\text{R}_2\text{-R}_3\text{-N,N-di-lower-alkylbenzamide}$ starting material is methyl, alkylation affords species where the 2-lower-alkyl group is either straight or branched depending upon whether a straight or branched chain lower-alkyl halide is used for the alkylation. On the other hand, when the 2-lower-alkyl group
20 in the starting material contains more than one carbon atom, alkylation takes place on the carbon atom adjacent the benzene ring and affords products having a sec.-lower-alkyl group at the 2-position.

- A particularly useful method for the preparation of
25 compounds IV where R_1 is n-lower-alkyl and R_2 and R_3 are hydrogen involves the protection of the benzylic protons of the starting material VII with a trialkylsilyl group, thereby permitting lithiation at the 6-position and formation of the sulfonamide as described above. This approach is illustrated
30 as follows wherein $\text{R}_{11}\text{-CH}_2$ is n-lower-alkyl.


This Sheet Has Been Replaced






A 2-n-lower-alkylbenzamide is silylated by forming the benzylic anion using an alkyl lithium or, preferably, a lithium dialkylamide (LDA) in an inert solvent, preferably THF, and treating with a suitable chlorotrialkylsilane, preferably chlorotrimethylsilane. The saccharin is synthesized as before, and the silyl group is removed by treatment with a source of fluoride anion, preferably cesium fluoride in DMF or tetra-n-butylammonium fluoride in an inert solvent.


Access to certain of the required saccharin and tetrahydrosaccharin intermediates in some cases requires building up the two rings making up the saccharin nucleus. Thus to prepare saccharins of formula IV where R₁ is lower-alkoxy, R₂ is 7-hydroxy and R₃ is hydrogen, 3,3-dithiobispropionic acid is converted to the bis acid chloride by reaction of the acid with thionyl chloride, and the acid chloride is then



reacted with two molar equivalents of benzylamine to produce the bis N-benzylamide. The latter, on reaction with sulfuryl chloride in an organic solvent, such as MDC, EDC or carbon tetrachloride, affords 5-chloro-2-benzyl-2H-isothiazol-3-one, which is oxidized with one molar equivalent of a peracid, such as perbenzoic acid or 3-chloroperbenzoic acid, to 5-chloro-2-benzyl-3(2H)-isothiazolone 1-oxide. The latter, on heating under pressure with a 2-lower-alkoxyfuran in an organic solvent, such as benzene, toluene or xylene, affords a 4-lower-alkoxy-7-hydroxy-2-benzyl-1,2-benzisothiazol-3(2H)-one 1-oxide. The 7-hydroxy group can, if desired, then be reacted with a lower-alkyl halide or a lower-alkyl-(O-lower-alkylene)_p-halide, where halide is bromide, chloride or iodide, to give the corresponding 4,7-di-lower-alkoxy or 4-lower-alkoxy-7-[lower-alkyl-(O-lower-alkylene)_p-O]-2-benzyl-1,2-benzisothiazol-3(2H)-one 1-oxide. Further oxidation of the product with one molar equivalent of a peracid as described above followed by catalytic debenzylation affords the corresponding 4-lower-alkoxy-7-hydroxy-saccharins. The method is illustrated as follows where Bz is benzyl:



When the 4,5,6,7-tetrahydrosaccharin of formula VIII is desired, the following modification is used:



VIII

This Sheet Has Been Replaced




The 5-chloro-2-benzyl-2H-isothiazole-3-one 1-oxide may be oxidized with a suitable oxidizing agent, preferably hydrogen peroxide in acetic acid, to the 1,1-dioxide which is then reacted under typical Diels Alder conditions with the appropriate diene and reduced to provide the 2-benzyl tetrahydrosaccharin which is hydrogenolyzed as before to the tetrahydrosaccharin VIII, which may then be converted to the intermediate 2-halomethyl derivative by the procedures described hereinbefore for the preparation of compound VI from compound IV.


Compounds of formula I wherein R_1 is lower-alkyl or phenyl and R_2 and R_3 are hydrogen may be synthesized by an alternate route from 2-cyclohexenone:

This Sheet Has Been Replaced





This Sheet Has Been Replaced




2-Cyclohexenone is reacted with the cuprate $(R_1)_2CuZ$, where Z is lithium or $Mg(X')_2$, where X' is bromide, chloride or iodide, followed by methyl cyanoformate and hexamethylphosphoramide (HMPA) according to the method of
5 Winkler et al. [Tet. Lett. 1987, 1051 and J. Org. Chem. 54, 4491 (1989)]. The resulting β -ketoester is reacted with benzylmercaptan in the presence of the acidic clay Montmorillonite KSF to produce a mixture of regioisomers of the benzylthioenol ether. The mixture is aromatized by
10 treatment with dichlorodicyanobenzoquinone (DDQ) and oxidized with chlorine gas in aqueous acid to provide the sulfonyl chloride ester, which may then be converted to the corresponding intermediate VI as shown earlier.


The 4,5,6,7-tetrahydrosaccharins which are the
15 starting materials for the compounds of formula II where R_6 is hydrogen are synthesized by a route similar to the preceding one:

This Sheet Has Been Replaced





This Sheet Has Been Replaced



A 3-lower-alkyl-2-cyclohexenone is reacted with the appropriate di-(lower-alkyl) lithium cuprate in an ethereal solvent, preferably diethylether, at -50 to +20°C, preferably about 0°C, and the resulting adduct is treated in situ with methyl cyanoformate and hexamethylphosphoramide. The 6,6-di-(lower-alkyl)-2-oxocyclohexane carboxylate so produced is reacted with benzyl mercaptan as described above and the mixture of 2-(benzylthio)cyclohexene carboxylates is oxidatively chlorinated as described above to provide a mixture of chlorosulfonyl esters that are treated with ammonia as before to yield the desired 4,4-di-(lower-alkyl)-4,5,6,7-tetrahydrosaccharin VIIIA, which may then be converted to the intermediate 2-halomethyl derivative as described hereinbefore.

It will be appreciated that each of the conversions of saccharin IV to 2-halomethylsaccharin VI described herein are equally applicable to the conversion of tetrahydrosaccharins VIII and VIIIA to the corresponding 2-halomethyl-tetrahydrosaccharins.

The phosphates, phosphonates and phosphinic acids of formula III belong to well known classes of phosphorus compounds. References disclosing such classes of phosphorus compounds and methods for their preparation are numerous, for example, M. Regitz, *Organische Phosphor-Verbindungen I and II*, Hauben-Weyl, *Methoden Der Organischen Chemie*, Vierte Auflage, Erweiterungs-Und-Folge-Bande, Bande E1 and E2, Georg Thieme Verlag Stuttgart-New York, 1982; Robert Engel, Ph.D., *Synthesis of Carbon-Phosphorus Bonds*, CRC Press, Inc., Boca Raton, Florida, 1988; J. Jankowska et al., *Synthesis* (1984), 408; K. Nagasawa, *Chem. and Pharm. Bull.* 7, 397 (1959); and J.G. Moffatt et al., *J. Am. Chem. Soc.* 79, 1194 (1957).

Simple chemical transformations which are conventional and well known to those skilled in the art of chemistry can be used for effecting changes in functional



groups in the compounds of the invention. For example, catalytic reduction of nitro groups to produce the corresponding amino substituted compounds, oxidation of sulfides or sulfoxides to prepare the corresponding, respective
5 sulfoxides or sulfones, saponification of esters to produce corresponding carboxylic acids, catalytic debenzylation of phenolic ethers, benzylamines or benzyl phosphates to produce the corresponding phenols, debenzylated amines and debenzylated phosphates, or reaction of phenols with an
10 alkylating agent in the presence of base or an alcohol in the presence of a coupling agent to produce ethers as desired can be carried out.

In standard biological test procedures, representative examples of compounds of the invention have been found
15 to possess human leukocyte elastase (HLE) inhibitory activity, and are thus useful in the treatment of degenerative diseases, such as emphysema, rheumatoid arthritis, pancreatitis, cystic fibrosis, chronic bronchitis, adult respiratory distress syndrome, inflammatory bowel disease, psoriasis, bullous
20 pemphigous and alpha-1-antitrypsin deficiency.

The compounds of the invention having basic functions can be converted to the acid-addition salt form by interaction of the base with an acid. In like manner, the free base can be regenerated from the acid-addition salt form in
25 conventional manner, that is by treating the salts with cold, weak aqueous bases, for example alkali metal carbonates and alkali metal bicarbonates. The bases thus regenerated can be interacted with the same or a different acid to give back the same or a different acid-addition salt. Thus the bases and all
30 of their acid-addition salts are readily interconvertible.

Likewise compounds of the invention having acid, i.e., carboxylic acid and phosphate, functions can be converted to salt forms thereof by reaction of the acid or phosphate with
35 a base, such as alkali metal or ammonium hydroxides or with organic bases such as alkyl, dialkyl or trialkylamines, and the

acids and phosphates can be regenerated from the salts by treatment of the salts with aqueous acids.

5 The compounds of the invention and their salts have inherent pharmacological activity of a type to be more fully described hereinbelow. This inherent pharmacological activity can be enjoyed in useful form for pharmaceutical purposes by employing the free bases or free acids themselves or the salts formed from pharmaceutically acceptable acids and bases; that is, acids or bases whose anions or cations are
10 innocuous to the animal organism in effective doses of the salts so that beneficial properties inherent in the common structural entity represented by the free bases and free acids are not vitiated by side effects ascribable to the anions or cations.

15 In utilizing this pharmacological activity of the salt, it is preferred, of course, to use pharmaceutically acceptable salts. Although water insolubility, high toxicity or lack of crystalline character may make some particular salt species unsuitable or less desirable for use as such in a given
20 pharmaceutical application, the water-insoluble or toxic salts can be converted to the corresponding pharmaceutically acceptable bases by decomposition of the salts with aqueous base or aqueous acid as explained above, or alternatively they can be converted to any desired pharmaceutically acceptable
25 salt by double decomposition reactions involving the anion or cation, for example by ion-exchange procedures.

Moreover, apart from their usefulness in pharmaceutical applications, the salts are useful as characterizing or identifying derivatives of the free bases or
30 free acids or in isolation or purification procedures. Like all of the salts, such characterization or purification salt derivatives can, if desired, be used to regenerate the pharmaceutically acceptable free bases or free acids by reaction of the salts with aqueous base or aqueous acid, or alternatively they can be



converted to a pharmaceutically acceptable salt by, for example, ion-exchange procedures.

5 The novel feature of the compounds then resides in the concept of the free bases and acids and the cationic and anionic forms of those compounds having basic and/or acid functions and not in any particular acid or base moiety or acid anion or base cation associated with the salt forms of the compounds; rather, the acid or base moieties or the anions or cations which can be associated with the salt forms are in
10 themselves neither novel nor critical and therefore can be any acid anion or base cation capable of salt formation with the bases or acids.

The compounds of the invention can be prepared for pharmaceutical use by incorporating them in unit dosage
15 form as tablets or capsules for oral administration either alone or in combination with suitable adjuvants such as calcium carbonate, starch, lactose, talc, magnesium stearate, gum acacia and the like. Still further, the compounds can be formulated for oral, parenteral or aerosol inhalation administration either
20 in aqueous solutions of water soluble salts of the compounds or in aqueous alcohol, glycol or oil solutions or oil-water emulsions in the same manner as conventional medicinal substances are prepared.

The percentages of active component in such
25 compositions may be varied so that a suitable dosage is obtained. The dosage administered to a particular patient is variable, depending upon the clinician's judgment using as criteria: the route of administration, the duration of treatment, the size and physical condition of the patient, the potency of
30 the active component and the patient's response thereto. An effective dosage amount of the active component can thus readily be determined by the clinician after a consideration of all criteria and using his best judgment on the patient's behalf.




5 The molecular structures of the compounds of the invention were assigned on the basis of study of their infrared and NMR spectra. The structures were confirmed by the correspondence between calculated and found values for elementary analyses for the elements. All melting points are uncorrected.

The invention will now be described with reference to the following examples which in no way limit the scope of the invention.

10

This Sheet Has Been Replaced



Exemplary Disclosure

Preparation of Starting Materials

Preparation 1

Powdered potassium hydroxide (7.4 g, 0.132 mol) was admixed with dimethylsulfoxide (DMSO) (100 ml), and the mixture was stirred for 5 minutes. 6-Methylantranilic acid (10.0 g, 0.066 mol) was then added to the mixture and iodomethane (4.52 ml, 0.073 mol) added dropwise. The reaction mixture was stirred for 30 minutes at room temperature, then diluted with 250 ml ether, washed with water (3 x 100 ml), dried over magnesium sulfate and concentrated. The crude product was filtered through a pad of flash grade (32-63) silica gel and eluted with 1:9 ether:hexane to afford 4.23 g (39%) of methyl 6-methylantranilate as an oil.

The methyl 6-methylantranilate so prepared (4.23 g, 0.026 mol) was dissolved in 25 ml acetic acid and the solution cooled to 0°C. Concentrated hydrochloric acid (45 ml) was added to produce a tan slurry. A solution of 1.89 g (0.027 mol) sodium nitrite in 8 ml water was added dropwise with stirring, the resulting orange solution was stirred at 0°C for 1 hour and then added in 6 portions to a mixture of 2.18 g (0.013 mol) cupric chloride dihydrate and sulfur dioxide (6.3 g) in 33 ml acetic acid and 6 ml water at 0°C. The dark green solution was stirred at room temperature overnight, poured into 300 ml ice-water, and the solid which separated was collected and dried by suction to provide 1.11 g methyl 2-chlorosulfonyl-6-methylbenzoate which was immediately added to 100 ml ice cold ammonium hydroxide and stirred at room temperature overnight. The solution was acidified to pH 1 with concentrated hydrochloric acid, and the resulting precipitate was collected and air-dried to provide 729 mg (12%) of 4-methylsaccharin, mp 224-226°C.





A mixture of 1.0 g (0.005 mol) 4-methylsaccharin, 0.33 g (0.001 mol) TBAB and 1.2 g (0.0075 mol) chloromethyl phenyl sulfide in 25 ml toluene was heated under reflux for about sixteen hours and then cooled, diluted with ethyl acetate and the solution washed with aqueous bicarbonate and water. The organic layer was dried and taken to dryness to give 0.74 g of 2-phenylthiomethyl-4-methylsaccharin.

The latter (0.74 g, 0.002 mol) was dissolved in 25 ml MDC and the solution treated dropwise over a period of about two hours with stirring with a solution of 0.47 g (0.003 mol) sulfur chloride in MDC and the reaction mixture taken to dryness. The yellow residual solid was triturated with hexane and filtered and dried to give 0.46 g of 2-chloromethyl-4-methylsaccharin as a pale yellow solid.

15 Preparation 2

Using the procedure described above in Preparation 1, 5.0 g (0.029 mol) 6-chloroanthranilic acid and 2.75 ml (0.044 mol) iodomethane were reacted in the presence of 4.08 g (0.073 mol) powdered potassium hydroxide to give 4.22 g (78%) of methyl 6-chloroanthranilate as an oil.

4-Chlorosaccharin was prepared by the same method as used for the preparation of 4-methylsaccharin using 4.22 g (0.023 mol) methyl 6-chloroanthranilate in 22 ml acetic acid and 40 ml concentrated hydrochloric acid and 1.68 g (0.024 mol) sodium nitrite in 7 ml water to prepare the diazonium salt which was added to 1.93 g (0.011 mol) cupric chloride dihydrate and 6.5 g sulfur dioxide in 30 ml acetic acid and 5 ml water. The resulting methyl 2-chloro-sulfonyl-6-chlorobenzoate was treated with 150 ml ammonium hydroxide as described above to afford 3.07 g (62%) of 4-chlorosaccharin as a pale yellow solid, mp 245-246°C.

2-Hydroxymethyl-4-chlorosaccharin was prepared by heating a solution of 1.00 g (0.0046 mol) 4-chlorosaccharin and 3.22 ml aqueous 37% formalin in ethanol. All attempts to

crystallize the viscous oily product resulted in decomposition to the starting material, and the product was thus used in the next step without characterization.

5 The crude 2-hydroxymethyl-4-chlorosaccharin so prepared (609 mg, 0.0025 mol) was admixed with 5 ml diethyl ether, and 3 ml thionyl chloride was added. The resulting mixture was heated to effect complete solution, stirred at room temperature overnight, diluted with 20 ml ether and filtered through a pad of celite topped with sand and eluted with
10 ether. Removal of the solvent afforded 430 mg crude chloromethyl derivative. A portion (225 mg) was removed for further reactions. The remainder (205 mg) was flash chromatographed on silica gel and eluted with 40% ether/-pentane to provide 137 mg of 2-chloromethyl-4-chloro-
15 saccharin, mp 135-136°C.

Preparation 3A

To a suspension of 6.0 g (0.03 mol) cuprous iodide in 100 ml THF was added 25 ml dimethyl sulfide, and the resulting yellow solution was cooled to -78°C and treated
20 dropwise with a solution of 23 ml (0.06 mol) 3.0 M solution of phenyl magnesium bromide in diethylether. The resulting pale yellow-orange solution was stirred at -78°C under nitrogen for one hour and then treated with 3.02 g (0.03 mol) 2-cyclohexenone in 10 ml THF. The resulting mixture was
25 allowed to warm to 0°C over a two hour period, recooled to -78°C, treated with 15 ml hexamethylphosphoramide, stirred for thirty minutes, treated with 8.0 g (0.09 mol) methyl cyanoformate and allowed to warm to ambient temperature overnight. The reaction mixture was poured into 100 ml
30 2N hydrochloric acid, and the organic phase was separated and the aqueous phase back-extracted with MDC. The combined organic extracts were taken to dryness in vacuo and the residue triturated with saturated ammonium chloride, then with water, then with brine and taken to dryness once again to

This Sheet Has Been Replaced



give 3.2 g of methyl 2-phenylcyclohexan-6-one carboxylate as an oil.

The latter (3.0 g, 0.013 mol), 4.8 g (0.039 mol) benzyl mercaptan and 1.0 g Amberlyst®-15 resin (Rohm and Haas) in chloroform was heated under reflux for twenty hours, the mixture treated with an additional 1.5 g of the resin and heated for an additional four hours. The mixture was then cooled to ambient temperature, filtered, the filtrate taken to dryness in vacuo, the residue triturated with hexane and the solid collected by filtration to give 0.85 g (19%) of a mixture of methyl 2-benzylthio-6-phenylcyclohex-2-ene carboxylate and methyl 2-benzylthio-6-phenylcyclohex-1-ene carboxylate, 0.6 g (0.0018 mol) of which was heated with 2.0 g 2,3-dichloro-5,6-dicyanobenzoquinone in 25 ml toluene with stirring under nitrogen for twenty-four hours. The mixture was filtered through a pad of silica gel, eluting with 2:1 MDC:hexane, and the eluate was taken to dryness to give 0.3 g (67%) of methyl 2-benzylthio-6-phenylbenzoate.

The latter (0.52 g, 0.0016 mol) dissolved in 10 ml MDC was diluted with 20 ml acetic acid and 5 ml water, the mixture cooled to -10°C, and chlorine gas was bubbled through the mixture until the exothermic reaction subsided. The mixture was then stirred for ten minutes and taken to dryness in vacuo to give 0.41 g (85%) of methyl 2-chloro-sulfonyl-6-phenylbenzoate which was dissolved in 10 ml THF and added to 25 ml of a solution of concentrated ammonium hydroxide while cooling in an ice/acetone bath. The reaction mixture was extracted with MDC, the organic phase discarded, and the aqueous layer acidified to pH 1 with concentrated hydrochloric acid and extracted with MDC. The organic extracts, on washing with brine, drying and evaporation to dryness, afforded 0.33 g (97%) of 4-phenylsaccharin.

Following a procedure similar to that described in Preparation 1, the latter (0.33 g, 0.0012 mol) was reacted with 0.3 g (0.0019 mol) chloromethyl phenyl sulfide in



15 ml toluene in the presence of 0.08 g (0.0025 mol) TBAB and the product, 2-phenylthiomethyl-6-phenylsaccharin (0.48 g, 100%), treated with sulfuryl chloride in MDC to give 0.36 g (95%) of 2-chloromethyl-4-phenylsaccharin.

5 Preparation 3B

To a suspension of anhydrous CuCN (2.16 g, 0.025 mol) in anhydrous ether (100 ml) at -78°C was added tert butyllithium (29.0 ml 1.7 M solution in pentane, 0.05 mol). After being stirred at -78°C for 1 hr and at -45°C for
10 30 minutes, the reaction mixture was recooled to -78°C. A solution of cyclohexenone (2.4 g, 0.025 mol) in ether (25 ml) was added and stirring continued for 15 minutes at -78°C and at -45°C for 30 minutes. The resulting mixture was recooled to -78°C, and HMPA (10 ml) in ether (25 ml) was added. After
15 5 min, methyl cyanoformate (2.55 g, 0.03 mol) in ether (25 ml) was added and the reaction warmed to 0°C over a 2 hr period. The resulting mixture was quenched with 2N HCl (100 ml), the layers separated, and the organic phase washed with saturated NH₄Cl solution (3 x 50 ml), water (2 x 50 ml), brine (1 x 50 ml)
20 and dried (Na₂SO₄). Removal of the solvent in vacuo and purification by Kugelrohr distillation (bath temperature 100-115°C at 0.6 mm) afforded 4.7 g (88%) of methyl-2-(1,1-dimethylethyl)cyclohexan-6-one carboxylate.

The cyclohexanone (4.6 g, 0.022 mol) was mixed
25 with benzylmercaptan (2.95 g, 0.024 mol) and the acidic clay montmorillonite, KSF (7.5 g) in anhydrous toluene (7.5 ml). The mixture was refluxed under nitrogen with azeotropic removal of water for 6 hr, cooled to room temperature and let stand overnight. The solids were filtered off and washed with
30 ether. The combined filtrate was washed with 10% Na₂CO₃, water, brine and dried. Removal of the solvent in vacuo and purification of the residue by flash chromatography on silica gel (10% ether in hexanes) gave 4.4 g (66%) of a mixture of methyl 2-benzylthio-6-(1,1-dimethylethyl)cyclohex-2-ene



carboxylate and 2-benzylthio-6-(1,1-dimethylethyl)cyclohex-1-ene carboxylate, which was stirred with DDQ (17.5 g, 0.077 mol) in toluene (50 ml) for 16 hr. The red reaction mixture was filtered through a 15 cm pad of silica gel, eluting with 6:3:1 hexanes:MDC:ether (1000 ml). The eluates were washed with 10% NaOH solution, water, brine and dried. Removal of the solvent in vacuo and purification by chromatography on silica gel (5% ether in hexanes) gave 1.6 g (40%) of methyl 2-benzylthio-6-(1,1-dimethyl)benzoate.

The benzylthiobenzoate (1.3 g, 0.004 mol) dissolved in MDC (5 ml) was diluted with acetic acid (25 ml) and water (2 ml); the mixture cooled to -10°C, and chlorine gas was bubbled until the exothermic reaction subsided. The mixture was then stirred for 10 minutes and taken to dryness in vacuo. Purification of the residue by flash chromatography on silica gel (1:1 hexanes:MDC) gave 0.8 g (67%) of methyl 2-chlorosulfonyl-6-(1,1-dimethylethyl)benzoate, which was dissolved in THF (5 ml) and added to a solution of concentrated ammonium hydroxide (25 ml) while cooling in an ice/acetone bath. After stirring at room temperature for 16 hr, the reaction mixture was concentrated in vacuo and acidified to pH 1 with 2N HCl. The separated solids were collected by filtration and crystallized from ether to give 0.64 g (95%) of 4-(1,1-dimethylethyl)saccharin, mp 185-187°C.

The 4-(1,1-dimethylethyl)saccharin (0.025 g, 1.0 mmol) was mixed with chloromethyl phenyl sulfide (0.25 g, 1.5 mmol) and tetrabutyl ammonium bromide (0.2 g, 0.6 mmol) in toluene (25 ml) and refluxed under nitrogen for 16 hr. The resulting mixture was cooled to room temperature, evaporated to dryness and purified by chromatography on silica gel (80%) MDC in hexanes to give 0.35 g (98%) of 2-phenylthiomethyl-4-(1,1-dimethylethyl)-saccharin, which was treated with sulfuryl chloride (0.25 g, 1.8 mmol) in MDC to give 0.21 g (75%) of 2-chloromethyl-4-(1,1-dimethylethyl)saccharin.



Preparation 4

A mixture of 3.22 g (0.012 mol) of 4-bromo-saccharin [Japanese Pat. Disclosure 58/79,034; C.A. 100, 7773w (1984)], 1.63 g (0.015 mol) potassium t-butoxide, 5 0.39 g (0.0012 mol) TBAB and 3.0 ml (0.022 mol) chloromethyl phenyl sulfide in 100 ml toluene was heated under reflux under a nitrogen atmosphere for eight hours and then stirred at ambient temperature for about sixteen hours. The reaction mixture was then diluted with ethyl acetate, and the organic 10 layer was washed with dilute potassium carbonate, water and brine, dried over magnesium sulfate and taken to dryness in vacuo. The residual solid was recrystallized from toluene-hexane to give 3.86 g (84%) of 4-bromo-2-phenylthiomethyl-saccharin, mp 174.5-178°C.

15 To a solution of the latter (3.27 g, 0.0085 mol) in 85 ml MDC was added, dropwise with stirring, 1.02 ml (0.0127 mol) sulfuryl chloride. The mixture was stirred at ambient temperature for an hour and a half, concentrated in vacuo and the residue triturated with hexane and filtered to 20 give 2.61 g of crude product which was recrystallized from toluene-hexane to give 2.24 g (85%) of 2-chloromethyl-4-bromosaccharin, mp 157-159°C.

Preparation 5

To a solution of 8.0 ml (0.053 mol) tetramethyl- 25 ethylenediamine (TMEDA) in 350 ml THF at -70°C was added 42 ml (0.055 mol) of a 1.3 M solution of s-butyl lithium in cyclohexane and the mixture was stirred for fifteen minutes. To the solution was added dropwise with stirring a solution of 10.36 g (0.050 mol) 2-methoxy-N,N-diethylbenzamide in 30 150 ml THF while maintaining the temperature at -60°C or below. After stirring for 20 minutes sulfur dioxide was bubbled into the reaction mixture, keeping the reaction temperature below -50°C, until the reaction mixture was acid to wet litmus paper. The mixture was stirred at ambient 35 temperature for two hours, diluted with 450 ml hexane, and

the solid material which had separated was collected, dissolved in 200 ml water and the mixture treated with 65 g sodium acetate and 21.5 g (0.19 mol) hydroxylamine-O-sulfonic acid in portions with stirring. The white solid which
5 separated was collected and dried to give 7.04 g (49%) of 2-aminosulfonyl-6-methoxy-N,N-diethylbenzamide, mp 190-194.5°C.

A mixture of the product (4.3 g, 0.015 mol) in 75 ml dioxane and 25 ml concentrated hydrochloric acid was
10 heated on a steam bath for 70 hours, then cooled, concentrated in vacuo, diluted with water and ice and rendered strongly basic with concentrated sodium hydroxide. The mixture was washed with MDC, and the aqueous layer was acidified with dilute hydrochloric acid and extracted with MDC. The extracts
15 were dried over magnesium sulfate and taken to dryness to give 1.29 g (40%) of 4-methoxysaccharin. In an alternative, and preferred, procedure, cyclization of 2-aminosulfonyl-6-methoxy-N,N-diethylbenzamide to 4-methoxysaccharin in 65% yield was carried out in refluxing glacial acetic acid for six
20 and a half hours.

Following a procedure similar to that described in Preparation 4 above, 1.14 g (0.0053 mol) of the latter was reacted with 1.31 ml (0.0097 mol) chloromethyl phenyl sulfide in toluene in the presence of 0.72 g (0.0064 mol) potassium
25 t-butoxide and 174 mg (0.00054 mol) tetrabutylammonium bromide to give 1.23 g (69%) of 4-methoxy-2-phenylthio-methylsaccharin, mp 152.5-154.5°C (from ethyl acetate-hexane), 1.02 g (0.003 mol) of which was treated with 0.36 ml (0.0045 mol) sulfuryl chloride in MDC to give
30 282 mg (36%) of 2-chloromethyl-4-methoxysaccharin, mp 169-174°C.

Preparation 6A

To a solution of 4.74 ml (0.031 mol) tetramethyl-ethylenediamine in 300 ml THF (passed through alumina prior
35 to use) was added 5.8 g (0.03 mol) 2-ethyl-N,N-diethyl-



benzamide. The solution was cooled to -78°C and treated with a solution of 34.9 ml (0.031 mol) of a 0.9 M solution of s-butyl lithium in cyclohexane. When addition was complete, the mixture was stirred for twenty minutes and then treated with a solution of 3.2 ml (0.04 mol) ethyl iodide while maintaining the temperature at -78°C . The temperature was then allowed to rise to ambient temperature and the mixture stirred for about sixteen hours and then poured into water. The resulting oil was separated and chromatographed on silica gel, eluting with 10% ethyl acetate/hexane to give 2.86 g (43%) of 2-sec.-butyl-N,N-diethylbenzamide as a yellow oil.

Following a procedure similar to that described in Preparation 5 above, the latter (10.45 g, 0.045 mol), dissolved in 70 ml THF, was added to a solution of 39.2 ml (0.047 mol) of a 1.2 M solution of s-butyl lithium in cyclohexane and 7.1 ml (0.047 mol) tetramethylethylenediamine in 250 ml THF while maintaining the temperature at -78°C . When addition was complete the mixture was stirred for an additional one half hour at -78°C and then treated with sulfur dioxide at -70°C and then allowed to warm to room temperature. The mixture was taken to dryness in vacuo, and the residue was dissolved in water and added with stirring to a cold solution of 15.2 g (0.134 mol) of hydroxylamine-O-sulfonic acid and 15.4 ml (0.134 mol) 35% sodium hydroxide to give 10.1 g (72%) of 2-aminosulfonyl-6-sec.-butyl-N,N-diethylbenzamide.

The latter (6.83 g, 0.22 mol) was dissolved in 100 ml glacial acetic acid and the solution heated under reflux for thirteen hours and then taken to dryness. The residue was triturated with diethyl ether and collected by filtration to give 5.7 g (83%) of the diethylammonium salt of 4-sec.-butyl-saccharin.

The latter (3.0 g, 0.0096 mol), on reaction with 1.13 ml (0.012 mol) chloromethyl phenyl sulfide in toluene, afforded 3.47 g (100%) of 2-phenylthiomethyl-4-sec.-butyl-saccharin.



Reaction of the latter (3.2 g, 0.0097 mol) with 2.3 ml (0.029 mol) sulfuryl chloride in 20 ml MDC afforded 2.4 g (87%) of 2-chloromethyl-4-sec.-butylsaccharin.


Preparation 6B

- 5 By a procedure analogous to that described for Preparation 6A, 9.2 g (32.9 mmol) 3,4-dimethoxy-2-propyl-N,N-diethylbenzamide was reacted with sulfur dioxide and 5.6 g (49.4 mmol) hydroxylamine-O-sulfonic acid to provide 7.4 g (63%) of 2-aminosulfonyl-4,5-dimethoxy-6-propyl-
10 N,N-diethylbenzamide which was cyclized in quantitative yield in acetic acid and phenylthiomethylated with 1.42 ml (15 mmol) chloromethyl phenyl sulfide to provide 4.07 g of 5,6-dimethoxy-2-phenylthio-4-propylsaccharin. Reaction of 3.59 g (8.8 mmol) of the phenylthioether with 2.12 ml
15 (26.4 mmol) sulfuryl chloride provided 2.84 g (97%) of 2-chloromethyl-5,6-dimethoxy-4-propylsaccharin.

The 3,4-dimethoxy-2-propyl-N,N-diethylbenzamide was obtained by the following procedure:

- To a solution of 0.216 moles n-butyllithium in
20 250 ml ether at ambient temperature was added dropwise 138.2 g (0.216 mol) veratrol in 100 ml ether and 32.6 ml (0.216 mol) of TMEDA. The reaction was stirred at ambient temperature for 14 hours and 21.9 ml (0.225 mol) n-propyl
1 hour at room temperature and worked up with aqueous
25 1N HCl to give 14 g (36%) of 2,3-dimethoxy-benzenepropane which was brominated with 14.52 g (81.6 mmol) N-bromo-succinimide on 36 g Kieselgel in 400 ml CCl₄ according to the method of Hisatoshi *et al.* [*Bull. Chem. Soc. Jap.* **32**, 591-593 (1989)] to give 19.6 g (98%) of 6-bromo-2,3-dimethoxy-
30 benzenepropane.

- The bromobenzene (14.2 g, 54.8 mmol) was dissolved in 200 ml ether, cooled to -78°C, and 25.2 ml (63 mmol) of 2.5 N n-butyllithium in hexane was added. The reaction was warmed to 0°C, held for an hour, and cooled to
35 -70°C, and 9 ml (71.2 mmol) of diethyl carbamyl chloride was



added. The reaction was allowed to come to room temperature and was quenched with saturated ammonium chloride. After extraction and drying, the product was crystallized from hexane to provide 9.5 g (62%) of 3,4-dimethoxy-2-propyl-N,N-diethylbenzamide, mp 65-67°C.

Preparation 6C

By a process analogous to that of Preparation 6B, 10.75 g (30 mmol) 2-aminosulfonyl-4,5-dimethoxy-6-isopropyl-N,N-diethylbenzamide was cyclized to provide 6.43 g of 5,6-dimethoxy-4-isopropylsaccharin (mp 186-188°C from ether-hexane), 5 g (17.5 mmol) of which was phenylthiomethylated with 2.48 ml (26.3 mmol) of phenylthiomethylchloride according to the procedure of Preparation 5, and chlorinated with 3 equivalents of sulfonyl chloride to provide an 85% yield of 2-chloromethyl-5,6-dimethoxy-4-isopropylsaccharin, mp 117-119°C from ethyl acetate-hexane.

The requisite benzamide was obtained from 2,3-dimethoxy- α -methylbenzeneethane by bromination followed by carbamylation as in Preparation 6B, to provide the intermediate 3,4-dimethoxy-2-isopropyl-N,N-diethylbenzamide. A solution of 66 ml 0.96M sec-butyllithium was added to 16.1 g (57.6 mmol) of the benzamide in 400 ml THF at -78°C under nitrogen. After stirring 2 hours the orange anion was cannulated into excess sulfur dioxide at -60°C. The reaction was allowed to come to room temperature and stirred for 18 hrs to remove SO₂. 10 ml sulfonyl chloride was added at 0°C and the reaction was stripped. The sulfonyl chloride was extracted into EtOAc-ether, washed with water, dried and stripped. The residue was dissolved in 80 ml THF and 17 ml conc. NH₄OH was added at 0°C. The reaction was stirred briefly at room temperature, stripped, and triturated in 2:1 ether-hexane to provide 12.89 g (62%) of 2-aminosulfonyl-4,5-dimethoxy-6-isopropyl-N,N-diethylbenzamide, mp 138-140°C.



Preparation 7

To a solution of 9.3 ml (0.058 mol) tetramethylethylenediamine in 340 ml THF at -78°C was added 52 ml of a 1.1 M solution (0.057 mol) of s-butyl lithium in cyclohexane.

5 The solution was then treated with a solution of 11.37 g (0.052 mol) 2-propyl-N,N-diethylbenzamide in 75 ml THF at -78°C and the solution stirred for fifteen minutes and then treated with a solution of 8.3 ml (0.104 mol) ethyl iodide in THF. The solution was stirred for an hour and a half at -78°C

10 and then quenched by the addition of saturated ammonium chloride added dropwise at -78°C . The mixture was then allowed to warm to ambient temperature, diluted with diethyl ether, washed first with dilute hydrochloric acid, then with water, then with saturated sodium bicarbonate, then with

15 brine, dried and taken to dryness to give 12.91 g of crude product which was chromatographed on silica gel, eluting with 10% ethyl acetate/hexane to give 3.23 g (25%) of 2-(3-pentyl)-N,N-diethylbenzamide as a yellow oil.

Following a procedure similar to that described in

20 Preparation 5 above, the latter (3.05 g, 0.0115 mol) in THF was reacted with 10.5 ml (0.126 mol) of a 1.2 M solution of s-butyl lithium in cyclohexane in the presence of 2.1 ml (0.014 mol) tetramethylethylenediamine. The resulting lithium salt was then reacted first with sulfur dioxide and then with sodium

25 hydroxylamine-O-sulfonate to give 1.97 g (52%) of 2-amino-sulfonyl-6-(3-pentyl)-N,N-diethylbenzamide as pale yellow crystals, mp $118-120^{\circ}\text{C}$ (soft 102°), 1.84 g (0.0056 mol) of which was cyclized in 22 ml refluxing glacial acetic acid to give 1.28 g (70%) of the diethylammonium salt of 4-(3-pentyl)-

30 saccharin, mp $107.5-109.5^{\circ}\text{C}$.

The latter (0.0037 mol), on reaction with 0.74 ml (0.0055 mol) chloromethyl phenyl sulfide in the presence of 116 mg (0.0004 mol) TBAB in 45 ml toluene, afforded 1.93 g of 2-phenylthiomethyl-4-(3-pentyl)saccharin

35 as a pale yellow oil, 1.93 g (0.0037 mol) of which, on reaction




with 0.59 ml (0.0073 mol) sulfuryl chloride in 37 ml MDC, afforded 1.2 g of 2-chloromethyl-4-(3-pentyl)saccharin as a pale yellow oil.

Preparation 8

5 A solution of 50.0 g (0.27 mol) 2,4-dimethoxybenzoic acid in 60 ml (98.0 g, 0.82 mol) thionyl chloride was heated under reflux for three hours, then cooled, and the excess thionyl chloride distilled off. The resulting 2,4-dimethoxybenzoyl chloride was dissolved in
10 150 ml MDC and the solution treated with a solution of 68 ml (48 g, 0.66 mol) diethylamine in 500 ml MDC, cooled to 0°C. When addition was complete the mixture was stirred for fifteen hours at ambient temperature, then washed with saturated sodium bicarbonate, water and brine and taken to
15 dryness and the residue distilled in vacuo to give 44.78 g (69%) of 2,4-dimethoxy-N,N-diethylbenzamide, bp 155-163°C/0.4 mm.

Following a procedure similar to that described in Preparation 5 above, 10.0 g (0.042 mol) of the product in
20 250 ml THF was reacted with 40.57 ml of a 1.1 M solution (0.044 mol) of s-butyl lithium in cyclohexane and 6.35 ml (0.042 mol) tetramethylethylenediamine in THF. The resulting lithium salt was then reacted first with about 40 ml sulfur dioxide and then with an aqueous solution
25 (0.13 mol) sodium hydroxylamine-O-sulfonate to give 8.26 g of 2-aminosulfonyl-4,6-dimethoxy-N,N-diethylbenzamide, 7.0 g of which (0.022 mol) was cyclized in 80 ml refluxing glacial acetic acid to give 6.6 g (94%) of the diethylammonium salt of 4,6-dimethoxysaccharin which was
30 used as such in the next step without further purification.

The latter (6.0 g, 0.019 mol), on reaction with 3.82 ml (0.028 mol) of chloromethyl phenyl sulfide in the presence of 0.611 g (0.0019 mol) TBAB in 200 ml toluene, afforded 6.2 g (89%) of 2-phenylthiomethyl-4,6-dimethoxy-
35 saccharin, 5.82 g of which (0.016 mol), on reaction with



3.23 g (0.0019 mol) sulfuryl chloride in 100 ml MDC, afforded 4.63 g (100%) of 2-chloromethyl-4,6-dimethoxysaccharin, mp 185-187°C.

Preparation 9A - 9G

- 5 Following a procedure similar to that described above in Preparation 5, substituting for the 2-methoxy-N,N-diethylbenzamide used therein an appropriate 2-R₁-R₂-R₃-substituted-N,N-diethylbenzamide, the following 4-R₁-R₂-R₃-2-halomethylsaccharins, where, in each instance,
- 10 R₃ is hydrogen, listed in TABLE A were prepared via the corresponding 2-phenylthiomethylsaccharins. Wherever available, the melting point (°C), recrystallization solvent and yield are given for each of the 2-unsubstituted saccharins, the 2-phenylthiomethyl-saccharins and the 2-chloromethyl-
- 15 saccharins in columns headed "mp/Solv." and "Yield". In all instances, the intermediate 2-phenylthiomethylsaccharins were used directly in the subsequent step without further characterization or purification.

This Sheet Has Been Replaced



TABLE A

Prep.	R ₁ /R ₂	Sacc.		2-C ₆ H ₅ SSCH ₂ -Sacc.		2-ClCH ₂ -Sacc.	
		mp/Solv.	Yield	mp/Solv.	Yield	mp/Solv.	Yield
9A	H 7-Cl	260-262	93	--	100	158.0-160.0 i-PrOH	51
9B	CH(CH ₃) ₂ H	177.0-178.0 MeOH	88	--	100	93.0-96.0 i-PrOH-Cyc. hex	100
9C	CH ₃ O 5-CH ₃ O	(a)	64	--	100	190.0-192.0	76
9D	COOCH ₃ H	(b) EtOAc-hex.	76	--	65	186.0-187.0	
9E	C ₂ H ₅ O H	(a)	96	--	95	139.0-140.0	97
9F	(CH ₃) ₂ CHO H		87	--	75	142.5-143.5	94
9G	C ₂ H ₅ 5,7-(CH ₃ O) ₂	i-PrOH	67	--	52	--	99

(a) Isolated and used in the next step as the diethylammonium salt.

(b) The 2-unsubstituted-saccharin was prepared by cyclization of dimethyl 3-aminosulfonylphthalate in methanol in the presence of a molar equivalent of sodium methoxide. The phthalate ester was prepared by diazotization of dimethyl 3-aminophthalate, decomposition of the diazonium salt with sulfur dioxide in the presence of cupric chloride and reaction of the resulting dimethyl 2-chlorosulfonylphthalate with ammonia. (84% yield overall).






water and ethyl acetate. The organic layer was washed with saturated sodium bicarbonate, then with brine, dried over sodium sulfate and taken to dryness to give 48.6 g (92%) methyl 2-hydroxy-5-(1.1.3.3-tetramethylbutyl)benzoate.

The latter dissolved in 250 ml DMF was treated first with 40.4 g (0.36 mol) 1,4-diazabicyclo[2.2.2]octane followed by 33.4 g (0.27 mol) N,N-dimethylchlorothiocarbamate and 100 ml DMF. The reaction mixture was heated at 45°C for about eight hours, cooled, poured into ice/water and concentrated hydrochloric acid and then extracted with ethyl acetate. The combined organic extracts were washed with dilute hydrochloric acid, then with sodium bicarbonate and then with brine, dried and taken to dryness to give 48.2 g (76%) of methyl 2-(N,N-dimethylthiocarbamyloxy)-5-(1.1.3.3-tetramethylbutyl)benzoate which was heated at 220°C for 15 hours, then cooled, dissolved in toluene and chromatographed on silica, eluting with 1:9 ethyl acetate:-toluene, to give 3.6 g (14%) of methyl 2-(N,N-dimethylcarbamylthio)-5-(1.1.3.3-tetramethylbutyl)benzoate.

A solution of the latter (0.025 mol) in 40 ml MDC was treated, with stirring, with 80 ml glacial acetic acid, followed by 16 ml water. The reaction mixture was cooled to 0°C, and chlorine was bubbled through the reaction mixture for about five minutes while maintaining the temperature between 5 and 24°C. The reaction was stirred for an additional 30 minutes, concentrated in vacuo, and the remaining solution poured into ice water. Extraction of the mixture with ethyl acetate and isolation of the product from the combined organic extracts afforded 6.8 g (78%) of methyl 2-chlorosulfonyl-5-(1.1.3.3-tetramethylbutyl)benzoate.

The product (9.0 g, 0.026 mol) was dissolved in THF and added to 100 ml concentrated ammonium hydroxide with cooling in an ice bath. The resulting solution was stirred for about 16 hours, then concentrated in vacuo and the concentrated solution acidified to pH 3 with concentrated



hydrochloric acid. The mixture was stirred for several hours, and the separated solid collected, washed with water and dried to give 9.0 g of 5-(1,1,3,3-tetramethylbutyl)saccharin, mp 213-215°C.

5 Following a procedure similar to that described in Preparation 11, 9.0 g (0.30 mol) of the product was reacted with thallium ethoxide in ethanol and the resulting thallium salt reacted with 3.33 g (0.021 mol) chloromethyl phenyl sulfide in DMF to give 5.76 g (66%) of 2-phenylthiomethyl-
10 5-(1,1,3,3-tetramethylbutyl)saccharin, 3.3 g (0.007 mol) of which was treated with 0.944 g sulfuryl chloride in MDC to give 1 g (41%) of 2-chloromethyl-5-(1,1,3,3-tetramethyl)butyl saccharin.

Preparation 13

15 Following a procedure similar to that described in Preparation 12 above, 15.5 g (0.086 mol) ethyl 2-hydroxy-6-methylbenzoate was reacted with 15.9 g (0.129 mol) N,N-dimethylchlorothiocarbamate in the presence of 19.3 g (0.172 mol) of 1,4-diazabicyclo[2.2.2]octane in DMF to
20 give 22.1 g (96%) of ethyl 2-(N,N-dimethylthiocarbamyloxy)-6-methyl-benzoate which was heated at 220°C for about 10 hours. The product was purified by chromatography on silica gel in MDC to give ethyl 2-(N,N-dimethylcarbamylothio)-6-methylbenzoate as a red-brown oil.

25 A solution of the latter (22.6 g, 0.0844 mol) in 170 ml MDC was treated with 340 ml glacial acetic acid and 68 ml water while cooling in an ice/acetone bath, and chlorine was bubbled through the reaction mixture for 10-15 minutes. The reaction vessel was evacuated to remove excess chlorine
30 and MDC and the mixture poured into water and partitioned between MDC and water. The organic layer, on drying and evaporation to dryness, afforded 19 g of ethyl 2-chloro-sulfonyl-6-methylbenzoate, 5 g (0.019 mol) of which was reacted with concentrated ammonium hydroxide in THF to
35 give 6.1 g (67%) of 4-methylsaccharin.

Following a procedure similar to that described in Preparation 11 above, the product (10.1 g, 0.0512 mol) was converted to the thallium salt by reaction with 12.8 g (0.0512 mol) thallium ethoxide in ethanol and the thallium salt reacted with 6.7 g (0.0427 mol) chloromethyl phenyl sulfide in DMF to give 6.85 g (50%) of 2-phenylthio-methyl-4-methylsaccharin.

Reaction of the latter (6.7 g, 0.021 mol) with sulfuryl chloride in MDC afforded 4.9 g (95%) of 2-chloro-methyl-4-methylsaccharin.

Preparation 14A

A mixture of 75 g (0.36 mol) 3,3-dithiobispropionic acid, 102 ml thionyl chloride and a catalytic amount of pyridine was stirred for about 24 hours and then evaporated to dryness in vacuo. The residue was treated with MDC and evaporated to dryness again to remove residual thionyl chloride and pyridine to give 87 g (98%) of the corresponding bis acid chloride, 44.8 g (0.18 mol) of which was dissolved in THF and added dropwise to a solution of 77.16 g (0.72 mol) benzylamine in THF. The mixture was stirred for two hours at 40-45°C, cooled and the precipitated solid collected, washed with water and dried to give 59 g (84%) of 3,3-dithiobispropionic acid N,N'-dibenzyl-carboxamide, mp 162-165°C.

Reaction of 7.0 g (0.018 mol) of the latter with 10.25 g (0.076 mol) sulfuryl chloride in MDC gave a mixture of 2-benzyl-2H-isothiazol-3-one and 5-chloro-2-benzyl-2H-isothiazol-3-one which were largely separated from one another by sonication in MDC (which solubilized most of the former). The insoluble material was collected by filtration and chromatographed on silica gel with MDC. There was thus obtained 5-chloro-2-benzyl-2H-isothiazol-3-one, mp 58-68°C.

A solution of 10 g (0.044 mol) of the latter in MDC was cooled to 0°C and the solution treated with



7.6 g (0.044 mol) 3-chloroperbenzoic acid, the mixture stirred for 10 minutes and then treated with a second 7.6 g portion of the perbenzoic acid. The reaction mixture was filtered, the filter washed with MDC and the filtrate washed with saturated sodium bicarbonate, then with brine, dried over sodium sulfate and taken to dryness and the residue chromatographed in MDC on silica gel, the product being eluted with 50:50 hexane:MDC, to give 7.15 g (46%) of 5-chloro-2-benzyl-2H-isothiazol-3-one 1-oxide.

10 A solution of 1.1 g (0.0045 mol) of the latter in 8 ml benzene was treated with 0.55 g (0.0051 mol) 2-methoxyfuran and the solution heated in a pressure bottle at 70°C for 1-1/2 hours and then cooled and the solid collected, washed with benzene and dried to give 2-benzyl-7-hydroxy-4-methoxybenzisothiazol-3-one 1-oxide, mp 235-237°C.

15 A mixture of the product (1.85 g, 0.006 mol), 2.48 g (0.018 mol) potassium carbonate and 1.70 g (0.012 mol) methyl iodide in acetone was heated under reflux for 1-1/2 hours and then cooled and poured into water. The solid which separated was collected by filtration, washed with water and dried to give 1.70 g (89%) of 2-benzyl-4,7-dimethoxybenzisothiazol-3-one 1-oxide, 1.13 g (0.0035 mol) of which was oxidized with 1.20 g (0.007 mol) of 3-chloroperbenzoic acid in MDC using the procedure described above to give 1.03 g (88%) of 2-benzyl-4,7-dimethoxysaccharin.

25 A mixture of 2.07 g (0.0062 mol) of the product, 1.37 g (0.02 mol) ammonium formate and 1.5 g 10% palladium-on-charcoal catalyst in 80 ml methanol was heated under reflux for one hour; then cooled and filtered, and the filtrate taken to dryness to give 0.92 g (57%) of the ammonium salt of 4,7-dimethoxysaccharin.

30 A solution of 1.11 g (0.0042 mol) of the ammonium salt was dissolved in DMF, 0.67 g (0.0042 mol) chloromethyl phenylsulfide was added, and the solution heated under reflux for eight hours and then cooled and poured into ice water.



The solid which separated was collected, washed with water and dried to give 0.50 g (33%) of 2-phenylthiomethyl-4,7-dimethoxysaccharin.

5 Reaction of the latter (0.5 g, 0.0013 mol) with sulfuryl chloride in MDC using the procedure described above in Preparation 4 afforded 0.22 g (58%) of 2-chloromethyl-4,7-dimethoxysaccharin.


Preparations 14B and 14C

10 Following a procedure similar to that described in Preparation 14A, other 2-chloromethylsaccharin derivatives were prepared as follows:

Preparation 14B

15 Reaction of 5.8 g (0.024 mol) 5-chloro-2-benzyl-2H-isothiazol-3-one-1-oxide with 3.76 g (0.0335 mol) 2-ethoxyfuran afforded 3.05 g (40%) of 2-benzyl-4-ethoxy-7-hydroxybenzisothiazol-3-one 1-oxide, 5.7 g of which was reacted with 3.6 g (0.0197 mol) of 2-(2-methoxyethoxy)ethyl bromide in the presence of 4.95 g (0.0358 mol) potassium carbonate in 125 ml methylethylketone and 25 ml DMF to give
20 7.0 g (93%) of 2-benzyl-4-ethoxy-7-[2-(2-methoxyethoxy)-ethoxy]benzisothiazol-3-one 1-oxide, which was oxidized as before with 3-chloroperbenzoic acid in MDC to give 2-benzyl-4-ethoxy-7-[2-(2-methoxyethoxy)ethoxy]saccharin.

25 Debenzylation of 6.6 g (0.015 mol) of the latter with 3.34 g (0.053 mol) ammonium formate in the presence of 6.4 g 10% palladium-on-charcoal catalyst in methanol afforded the ammonium salt of 4-ethoxy-7-[2-(2-methoxyethoxy)-ethoxy]saccharin, which was reacted with 2.38 g (0.015 mol) of chloromethyl phenyl sulfide in 100 ml DMF to give 1.46 g
30 (21%) 2-phenylthiomethyl-4-ethoxy-7-[2-(2-methoxyethoxy)-ethoxy]saccharin, mp 73-75°C (from isopropanol). Treatment of 1.4 g (0.0029 mol) of the product with 0.4 g (0.0029 mol) sulfuryl chloride in MDC afforded 1.16 g (100%) of 2-chloromethyl-4-ethoxy-7-[2-(2-methoxyethoxy)ethoxy]saccharin.




Preparation 14C

Reaction of 3.03 g (0.01 mol) 2-benzyl-7-hydroxy-4-methoxybenzothiazol-3-one-1-oxide (Preparation 14A) with 2.01 g (0.011 mol) of 2-(2-methoxyethoxy)ethyl bromide in methylethylketone in the presence of 2 g (0.015 mol) potassium carbonate afforded 2.58 g (64%) of 2-benzyl-4-methoxy-7-[2-(2-methoxyethoxy)ethoxy]benzothiazol-3-one-1-oxide, which, on oxidation with 1.1 g (0.0063 mol) 3-chloroperbenzoic acid in MDC, gave 2-benzyl-4-methoxy-7-[2-(2-methoxyethoxy)ethoxy]saccharin. Debenzylation of 0.25 g (0.0006 mol) of the product with 0.13 g (0.0021 mol) ammonium formate in methanol in the presence of 0.25 g, 10% palladium-on-charcoal gave 0.21 g (100%) of the ammonium salt of 4-methoxy-7-[2-(2-methoxyethoxy)ethoxy]saccharin. Reaction of 1.4 g (0.004 mol) of the ammonium salt with 0.63 g (0.004 mol) chloromethylphenyl sulfide in DMF afforded 2-phenylthiomethyl-4-methoxy-7-[2-(2-methoxyethoxy)ethoxy]saccharin, which, on reaction with sulfuryl chloride in MDC, afforded 0.53 g (35%) of 2-chloromethyl-4-methoxy-7-[2-(2-methoxyethoxy)ethoxy]saccharin.

Preparation 15

A solution of 1.89 g (0.011 mol) diethylamino sulfur trifluoride (DAST) in 20 ml MDC was added to a suspension of 2.13 g (0.01 mol) 2-hydroxymethylsaccharin in 25 ml MDC while maintaining the reaction mixture at -78°C.

The reaction mixture was stirred at -78°C for one hour, the temperature allowed to slowly rise to ambient temperature, the mixture stirred for 16 hours and then poured into ice-water. The organic layer was separated and washed with water, dried over magnesium sulfate and taken to dryness to give 2.2 g of product which was recrystallized from ethyl acetate to give 1.6 g (74%) of 2-fluoromethylsaccharin, mp 96-98°C.



Preparation 16A

To a solution of 0.5 g (0.0025 mol) 4-methylsaccharin in THF cooled to -78°C by a dry ice/acetone bath was added, dropwise with stirring, a solution of 5.2 ml of a
5 1.3 M solution of s-butyl lithium in cyclohexane. The mixture was stirred an additional hour at -78°C and then treated with 0.16 ml (0.025 mol) methyl iodide over a 1-1/2 hour period. The mixture was stirred for an hour and 45 minutes, quenched in 25 ml 1N hydrochloric acid, the reaction mixture rendered
10 basic, the aqueous mixture extracted with chloroform and then acidified and extracted with ethyl acetate. The combined organic extracts were washed with 10% sodium thiosulfate, then with brine, dried over sodium sulfate and taken to dryness to give a product, whose PMR spectrum indicated a
15 mixture consisting of 74% 4-ethylsaccharin and 21% 4,7-dimethylsaccharin.

Following a procedure similar to that described in Preparation 4 above, the crude material (0.47 g, 0.0022 mol) was reacted with 0.24 ml (0.0028 mol) chloromethyl phenyl
20 sulfide in toluene in the presence of tetrabutylammonium bromide, and the product chromatographed on silica gel, eluting with MDC, 5 ml fractions being collected. The first 420 ml of eluate were discarded. The next 20 fractions, on evaporation, afforded 0.07 g of material, predominantly
25 2-phenylthiomethyl-4,7-dimethylsaccharin, which was set aside. The next 25 fractions afforded 0.37 g of 2-phenylthio-
methyl-4-ethylsaccharin, which was reacted with sulfuryl
chloride in MDC to give 0.19 g (66%) of 2-chloromethyl-
4-ethylsaccharin.

30 Preparation 16B

Following a procedure similar to that described in Preparation 16A, 10 g (0.051 mol) 4-methylsaccharin in THF was reacted with 86 ml (0.10 mol) of a 1.18 M solution of s-butyl lithium in cyclohexane and the resulting solution
35 treated with 4.5 ml (0.050 mol) ethyl iodide to give



10.15 g (89%) of 4-propylsaccharin, which, on reaction with 5.32 ml (0.056 mol) chloromethyl phenyl sulfide in toluene in the presence of tetrabutylammonium bromide, afforded a crude mixture from which was isolated by flash chromatography on silica gel 2-phenylthiomethyl-4-propylsaccharin as an oil, 1.8 g (0.0052 mol) of which, on reaction with 1.25 ml (0.016 mol) sulfuryl chloride in MDC, afforded 0.94 g (66%) of 2-chloro-methyl-4-propylsaccharin.

Preparation 16C

10 A preferred alternative to Preparation 16A is as follows:

To a solution of 5.13 g (25 mmol) N,N,2-triethylbenzamide in THF (50 ml) at -78°C was added a solution of LDA (Aldrich 2.0M, 15.63 ml, 31.25 mmol). The solution was warmed to -10°C with ice water over 1 hr, then cooled to -78°C with dry ice-acetone. TMSCl (6.34 ml, 50 mmol) was added neat at -78°C and then reaction brought to room temperature after 1 hr. The reaction was quenched with saturated NH₄Cl and extracted with ether (2 x 100 ml), dried over MgSO₄, stripped and the residue distilled in a Kugelrohr (130-140°C, 0.65 mm) to obtain 6.51 g (94%) of N,N-diethyl-2-[1-(trimethylsilyl)ethyl]benzamide.

To a solution of sec BuLi (0.97M, 5.10 ml, 4.96 mmol), TMEDA (0.75 ml, 4.96 mmol) in THF at -78°C was added the amide (1.25 g, 4.50 mmol) in THF. Excess SO₂ in THF was added quickly at -78°C then warmed to room temperature. The THF was removed in vacuo then reacted at 0°C with two equivalents of a 1:1 solution of sodium hydroxide (0.36 g, 9.0 mmol) and hydroxylamine-O-sulfonic acid (1.0 g, 9.0 mmol) in H₂O. The reaction was stirred at room temperature for 4 hrs, extracted with EtOAc and flash chromatographed on silica gel with 20% ethyl acetate/hexane to give 0.62 g (47%) of 2-aminosulfonyl-N,N-diethyl-6-[1-(trimethylsilyl)ethyl]benzamide. The benzamide (0.95 g,





2.66 mol) was refluxed in glacial acetic acid (20 ml) for 18 hr, stripped to dryness, triturated with hot cyclohexane (30 ml) and a trace of EtOAc (3 ml), cooled with scratching and filtered. There was obtained 0.81 g (85%) of 4-[1-(trimethylsilyl)ethyl]-
5 saccharin, mp 123-125°C.

To the trimethylsilylethylsaccharin (0.25 g, 0.70 mmol) in DMF (9 ml) at room temperature was added H₂O (1 ml) and cesium fluoride (0.75 g, 4.94 mmol, 7 equivalents). After 7 hr the reaction was poured into
10 5% NaOH and extracted with EtOAc. The aqueous layer was acidified with 12N HCl and extracted with Et₂O-EtOAc (1:1), dried over Na₂SO₄, filtered and stripped to give a colorless solid in quantitative yield. It was recrystallized from 5% Et₂O-hexanes to give 0.091 g (64%) of 4-ethylsaccharin,
15 mp 183-185°C.

Preparation 17

The 0.07 g sample of material obtained in the early fractions from the chromatographic separation described above in Preparation 16A consisting predominantly of
20 2-phenylthiomethyl-4,7-dimethylsaccharin was reacted with 0.05 ml sulfuryl chloride in MDC and the product recrystallized from cyclohexane-ethyl acetate to give 20 mg (51%) of 2-chloromethyl-4,7-dimethylsaccharin, mp 107-108°C.

Preparation 18A

To a solution of 40.0 g (0.174 mol) 2-isopropyl-4-methoxybromobenzene in 600 ml diethylether at 0°C was added 103.68 ml (0.175 mol) of a 1.69 M solution of butyl lithium in diethylether. When the addition was complete the solution was cooled to 0°C for one hour and stirred for an
30 additional five hours at ambient temperature, then recooled to -78°C and treated with a solution of 23.68 g (0.175 mol) N,N-diethylcarbonyl chloride in 80 ml diethylether. The resulting solution was stirred for about 12 hours while the reaction temperature was allowed to rise and then quenched
35 with saturated ammonium chloride solution. The aqueous and

organic layers were separated, the aqueous layer back-extracted with ethyl acetate and the combined organic extracts washed once with brine, then dried and the solution taken to dryness to give a crude product which was flashed chromatographed on silica gel, eluting with 30% ethyl acetate/hexane to give 34.4 g (79%) of 2-isopropyl-4-methoxy-N,N-diethylbenzamide as an oil which was used as such in the next step without further purification. The oil can be distilled, if desired, and boils at 123-129°C/0.2-0.3 mm.

Following a procedure similar to that described in Preparation 5 above, the latter (15.0 g, 0.060 mol) in 100 ml diethylether was reacted with 77.8 ml (0.784 mol) of a 1.2 M solution of s-butyl lithium in cyclohexane in the presence of 6.98 g (0.06 mol) tetramethylethylenediamine. The resulting lithium salt was then reacted first with 50 ml sulfur dioxide and then with 0.181 mol sodium hydroxylamine-O-sulfonate to give 11.6 g (59%) of 2-amino-sulfonyl-6-isopropyl-4-methoxy-N,N-diethylbenzamide, mp 103-105°C (from ethyl acetate/hexane), 11.0 g (0.034 mol) of which was cyclized in 200 ml refluxing glacial acetic acid to give 10.3 g of the diethylammonium salt of 4-isopropyl-6-methoxysaccharin, mp 132-135°C.

The latter (0.030 mol), on reaction with 6.14 ml (7.25 g, 0.046 mol) of chloromethylphenylsulfide in the presence of 0.98 g (0.003 mol) TBAB in 250 ml toluene, afforded 10.1 g (88%) of 2-phenylthiomethyl-4-isopropyl-6-methoxysaccharin as an oil, 9.7 g (0.026 mol) of which, on reaction with 3.1 ml (5.21 g, 0.039 mol) sulfuryl chloride in MDC, afforded 6.9 g (88%) of 2-chloromethyl-4-isopropyl-6-methoxysaccharin, mp 151-152°C.

Preparation 18B

An alternative procedure was also followed:

To a solution of 300 ml N,N,N',N'-tetramethylethylenediamine (TMEDA) (1.99 moles) in 4 l anhydrous ether was added 1550 ml of sec-BuLi (1.3 M) and the system was



cooled to -70°C under a nitrogen atmosphere. A solution of 454.2 g 2-isopropyl-4-methoxy N,N-diethylbenzamide (1.82 moles) in 300 ml anhydrous ether was added dropwise over 30 minutes (the temperature was maintained at or below -60°C during the addition). After the addition was complete, the reaction was stirred at -70°C for one hour and allowed to warm to -50°C . After holding the temperature at -50°C for 30 minutes, the mixture was cooled back to -70°C . To this stirred solution was added via cannulating tube a solution of 200 g SO_2 in 200 ml dry ether precooled to -40°C under positive nitrogen pressure over a 20-minute period. The temperature of the reaction mixture during the addition was maintained below -40°C . (A white powdery precipitate of aryllithium sulphinate separated out almost immediately). After the addition, the ice-bath was removed and the reaction was allowed to stir at ambient temperature for two hours. It was cooled to -5°C and to this stirred solution was added 190 ml sulfuryl chloride (2.36 moles) dropwise over a 15-minute period maintaining the temperature below 10°C during the addition. After further stirring for 30 minutes at $0-5^{\circ}\text{C}$, a white insoluble precipitate was filtered off and washed with 2 l of anhydrous ether. Removal of the solvent at atmospheric pressure afforded the sulfonyl chloride as a crude dark oil. This crude sulfonyl chloride was dissolved in 1.4 l THF, cooled to -10°C , and 540 ml concentrated NH_4OH (28%) was added in portions over 15 minutes (the temperature was kept at 15°C or below throughout the addition). After stirring for 15 minutes at ambient temperature, the THF and excess ammonia were removed under vacuum to give a dark oil, which was diluted with 6.0 l of water and acidified with 3N HCl to pH 1. The light yellow solid was collected by filtration and washed with 800 ml water. The solid was dried at 60°C under vacuum for 18 hours and recrystallized from a mixture of 800 ml ethyl



acetate and 3 l hexane to give 429 g (72%) of 2-aminosulfonyl-6-isopropyl-4-methoxy-N,N-diethylbenzamide, mp 122-125°C.

5 A solution of 429.6 g of the diethylbenzamide (1.31 mole) in 1.5 l acetic acid was refluxed for 20 hours. It was cooled to room temperature and the solvent removed under vacuum. The oily residue was dissolved in 6 l water and adjusted to pH 1 with 6N HCl. The crude product was collected by filtration and washed with 2 l water. The solid was dried at 60°C under vacuum for 18 hours and
10 recrystallized from ethyl acetate/hexane to give 303 g (91%) 4-isopropyl-6-methoxysaccharin, mp 188°C.

To a suspension of 24 g paraformaldehyde (0.8 mole) and 86.4 g chlorotrimethylsilane (1.6 moles) in 200 ml 1,2-dichloroethane was added 0.8 ml anhydrous
15 tin(IV) chloride and the resulting solution stirred on a steam bath for one hour. At the end of this period, 51 g 4-isopropyl-6-methoxysaccharin (0.2 mole) was added to the clear solution and the reaction mixture was further refluxed for 18 hours. It was cooled to room temperature, poured into water, the
20 organic layer separated and washed with 50 ml 2N sodium hydroxide solution. The organic layer was dried over anhydrous magnesium sulfate and concentrated under vacuum to give crude product. It was purified by crystallization from ethyl acetate/hexane to give 57 g (87%) of 2-chloromethyl-4-isopropyl-6-methoxysaccharin, mp 151°C.
25

Preparation 19

To a solution of 1.0 g (0.0039 mol) 4-isopropyl-6-methoxysaccharin in 15 ml MDC was added at ambient temperature 1.28 g (5.12 ml) of a 1 M solution of boron tri-
30 bromide in MDC. When addition was complete the reaction mixture was heated under reflux for about five hours, cooled, taken to dryness in vacuo and the residue treated with ice and saturated sodium bicarbonate. The aqueous solution was extracted once with ethyl acetate and then acidified to pH 1
35 with concentrated hydrochloric acid. Extraction of the mixture



with ethyl acetate/diethyl ether (8:2), drying the organic extracts and removal of the solvent in vacuo afforded 0.9 g (96%) of 6-hydroxy-4-isopropylsaccharin as a white crystalline solid which was used as such in the next step.

5 An alternative procedure was also used. To a stirred suspension of 62.74 g (0.47 mol) AlCl_3 in 500 ml chloroform at 0°C was added 43.9 g (0.7 mol) ethanethiol. Within minutes a clear solution formed. To this a solution of 20.0 g (0.078 mol) 4-isopropyl-6-methoxysaccharin in
10 550 ml chloroform was added over a 30-min period. This solution was allowed to warm to RT and stirred for 3-4 hr at 60°C . After cooling, the mixture was poured into ice-water and acidified with dilute HCl. The solid which separated was collected by filtration, washed with water and dried to give
15 18.4 g (97%) of 6-hydroxy-4-isopropylsaccharin.

Following a procedure similar to that described in Preparation 4 above, the latter (0.004 mol) was reacted with 0.61 ml (0.0046 mol) chloromethyl phenyl sulfide in toluene in the presence of 0.133 g (0.004 mol) TBAB to give 0.32 g (21%)
20 of 6-hydroxy-4-isopropyl-2-phenylthiomethylsaccharin, mp $127-129.5^\circ\text{C}$, 1.78 g of which was treated with 0.43 ml (0.73 g) sulfuryl chloride in MDC to give 1.2 g (84%) of 2-chloromethyl-6-hydroxy-4-isopropyl-saccharin, mp $149-150^\circ\text{C}$.

25 Preparation 19A

Following procedures similar to those described in Preparation 19, 4-methoxysaccharin can be converted successively to 4-hydroxysaccharin, 4-hydroxy-2-phenylthio-methylsaccharin and 2-chloromethyl-4-hydroxysaccharin.

30 Preparation 20

5g (0.0207 mol) of 6-hydroxy-4-isopropyl-saccharin was dissolved in 150 ml methanol and 3.4 g (0.0104 mol) Cs_2CO_3 was added. The mixture was stirred for 3-4 hr at RT. The excess methanol was removed under
35 reduced pressure and the residue was dried for 2 hr under



high vacuum. The residue was then dissolved in 110 ml DMF and 0.32 g (0.0209 mol) chloromethyl phenyl sulfide was added. The stirred mixture was heated at 70-75°C for 12 hr, cooled, treated with ice water and extracted with 600 ml 4:1 ethyl acetate:ether. The organic layer was washed with water and saturated NaCl and dried. The solvent was removed under reduced pressure. The residue was purified by flash chromatography with 20% ethyl acetate in MDC. There was obtained 4.5 g (60%) of 6-hydroxy-4-isopropyl-2-phenyl-thiomethylsaccharin, mp 150-151.5°C which, on reaction with sulfuryl chloride as described in Preparation 19, yielded 2-chloromethyl-6-hydroxy-4-isopropylsaccharin as before.

Preparation 21

To a solution of 5-chloro-2-benzyl-4-isothiazolin-3-one (*J. Het. Chem.* 8, 571, 1971) (9.4 g, 0.04 mol) in MDC (100 ml) was added in one portion 80-85% 3-chloroperoxybenzoic acid (10.8 g, 0.06 mol) and the resulting mixture stirred at room temperature overnight under nitrogen. The precipitated solids were filtered off and washed with MDC (50 ml). The combined filtrate was evaporated to near dryness and the residue partitioned between ethyl acetate (300 ml) and saturated NaHCO₃ (100 ml). The layers were separated and the organic phase washed with saturated NaHCO₃ (2 x 100 ml), brine (1 x 100 ml) and dried. Removal of the solvent *in vacuo* afforded 10.0 g (99%) of 5-chloro-2-benzyl-4-isothiazolin-3(2H)-one 1-oxide as a pale yellow oil.

The 1-oxide (10.0 g, 0.04 mol) in glacial acetic acid (200 ml) was treated with 30% H₂O₂ (100 ml, 0.88 mol) and heated on a steam bath for 2 hr during which time an additional 30 ml (0.26 mol) 30% H₂O₂ was added. After heating on a steam bath for an additional hour, the reaction mixture was cooled to room temperature and poured into ice cold water (1 l) and stirred. The precipitated solids were collected by filtration, washed with water (2 x 100 ml), hexanes and air-dried to give 4.8 g (45%) of 5-chloro-



2-benzyl-4-isothiazolin-3(2H)-one 1,1-dioxide as a colorless solid.

The dioxide (1.2 g, 4.7 mmol) was mixed with 2.02 g (11 mmol) of 2-trimethylsiloxy-5-methylhexa-
5 1,3-diene (prepared from 5-methylhex-3-ene according to the method of E.J. Corey *et al.*, *Tet. Lett.* 495, 1984) in toluene (50 ml) and refluxed for a period of 20 hr under nitrogen. The resulting mixture was cooled to room temperature and concentrated *in vacuo*. The residue was
10 dissolved in THF (25 ml) and treated with 2N HCl (10 ml). After stirring under nitrogen at room temperature for 10 min, ether (100 ml) was added and the layers separated. The organic phase was washed with water, brine, dried and evaporated to dryness to give a pale yellow foam. The foam
15 was dissolved in toluene (30 ml), DBN (1.5 ml) was added and stirred at room temperature for 2 hr. MDC (100 ml) and 2N HCl (50 ml) were added and stirring continued for 5 min. The layers were separated and the organic phase washed with water, brine and dried. Removal of the solvent *in vacuo* and
20 purification of the residue by flash chromatography on silica gel (5:4:1, hexanes:MDC:ether) gave 0.6 g (39%) of 2-benzyl-4-isopropyl-6-oxo-tetrahydrosaccharin as a pale yellow foam.

The tetrahydrosaccharin (0.59 g, 1.7 mmol) was dissolved in toluene (50 ml), dimethylamine hydrochloride
25 (1.5 g, 18.0 mmol) and 4 A sieves (2.0 g) were added. The resulting mixture was refluxed with azeotropic removal of water for 96 hr. It was necessary to add additional dimethylamine hydrochloride (0.8 g, 10.0 mmol) and 4 A sieves every 12 hr during this 96 hr period at the end of which time, the
30 reaction mixture was cooled to room temperature and filtered. The filter cake was washed with diethylether (100 ml) and the combined filtrates were concentrated *in vacuo* to give 0.63 g (99%) of 2-benzyl-4-isopropyl-6-dimethylamino-(4,5)-dihydrosaccharin as a pale yellow solid.

35



To a solution of the dihydrosaccharin (0.63 g, 1.7 mmol) in refluxing chloroform (50 ml) was added activated manganese dioxide (4.3 g, 49.5 mmol) in portions over a period of 4 hr. After the addition of the last portion of manganese dioxide, the reaction was refluxed for an additional hour, cooled to room temperature and filtered through a pad of Super-Cel, eluting with ethyl acetate. The combined eluates were concentrated in vacuo and the residue purified by flash chromatography on silica gel (5:4:1, hexanes:MDC:ether) to give 0.32 g (50%) of 2-benzyl-4-isopropyl-6-dimethylamino-saccharin as a colorless solid.

The 2-benzylsaccharin (0.32 g, 0.9 mmol) in methanol (20 ml) was treated with ammonium formate (0.24 g, 3.8 mmol) and 10% Pd on Carbon (0.25 g) and refluxed for 1 hr, cooled to room temperature and filtered through a pad of Super-Cel, eluting with methanol (100 ml). The combined eluates were concentrated in vacuo. The residue was dissolved in MDC (10 ml), glacial acetic acid (0.25 ml) was added, stirred for 5 min and evaporated to dryness in vacuo to give 0.25 g (100%) of 4-isopropyl-6-dimethylaminosaccharin as a colorless foam.

Following a procedure similar to that described in Preparation 1, a mixture of 4-isopropyl-6-dimethylaminosaccharin (0.27 g, 1.0 mmol), chloromethyl phenylsulfide (0.32 g, 2.0 mmol) and tetrabutylammonium bromide (0.1 g, 0.2 mmol) in toluene was converted to 0.22 g (56%) 2-phenylthiomethyl-4-isopropyl-6-dimethylaminosaccharin which was treated with sulfuryl chloride (1.86 ml 0.31 M solution, 0.6 mmol) to give 0.15 g of a yellow gum that contained 25% (by NMR) of 2-chloromethyl-4-isopropyl-6-dimethylamino-7-chlorosaccharin.

Preparation 22

Thirty-one grams of 4-isopropyl-1,2-dimethoxybenzene was treated with N-bromosuccinimide followed by butyllithium and diethyl carbamyl chloride as in



Preparation 6B to yield 15.2 g 2-isopropyl-4,5-dimethoxy-N,N-diethylbenzamide as a viscous oil. The benzamide was treated according to Preparation 18B with butyllithium and sulfur dioxide followed by sulfuryl chloride then ammonia to provide 4.5 g of the sulfonamide, mp 181-182°C from ether. This was cyclized in acetic acid as in Preparation 18B to obtain 2.86 g of 6,7-dimethoxy-4-isopropylsaccharin, mp 210-212°C from ethyl acetate-hexane.

To a solution of 0.5 g 4-isopropyl-6,7-dimethoxy-saccharin in 3 ml of DMF was added 0.5 ml of diisopropylethylamine at room temperature. After 15 min, 0.35 g chloromethylphenylsulfide was added and the mixture heated at 80°C for 16 hr. The reaction mixture was poured into EtOAc and washed with aqueous Na₂CO₃ solution, aqueous 2N HCl solution, saturated aqueous NaCl solution. The organic layer was dried over Na₂SO₄ and the solvents removed. Chromatography with MDC gave 0.35 g of desired product, which was used immediately. Treatment of the 0.35 g sample of phenylthiomethylsaccharin in 3 ml of MDC with 0.1 ml sulfuryl chloride for 30 min at 20°C followed by removal of solvents and trituration with hexane gave 0.3 g of 2-chloromethyl-6,7-dimethoxy-4-isopropylsaccharin.

Preparation 23

To a solution of 5.7 g methyl piperonylate in 20 ml dry ether was added 30 ml 3.0 methyl magnesium bromide in ether at 0°C over 20 min. The mixture was stirred for 20 hr then diluted with 200 ml ether and washed with water. The organic layer was dried with Na₂SO₄ and the solvents removed to yield 5.6 g crude 3,4-dimethoxy-(1'-hydroxy-1'-methylethyl)benzene. This material was immediately treated in 50 ml acetic acid with 1 g 10% Pd/C under 50 psi of hydrogen for 20 hr. Filtration to remove catalyst and removal of solvent yielded 4.5 g of 5-isopropyl-1,3-benzodioxole. The isopropyldioxole was brominated,



amidated, sulfonated and cyclized as in Preparation 22 to yield 700 mg of 4-isopropyl-6,7-methylenedioxysaccharin, mp 226-228°C from ethyl acetate/hexane. 500mg of the saccharin was chloromethylated as in Preparation 22 to provide 300 mg of 2-chloromethyl-4-isopropyl-6,7-methylenedioxysaccharin, mp 174-176°C.

Preparation 24

Following the procedure of Preparation 18A, 5 g 2-bromo-N,N-dimethylaniline was converted to 3.5 g N,N-diethyl-2-dimethylaminobenzamide. The amide was reacted by the method of Preparation 18B to provide 65 mg 4-dimethylaminosaccharin, mp 228-229°C from ether-hexane.

Reaction of 4-dimethylaminosaccharin with chloromethylphenylsulfide in the presence of potassium t-butoxide and tetrabutylammonium bromide affords 4-dimethylamino-2-phenylthiomethylsaccharin. Reaction of the latter with sulfur chloride in MDC affords 4-dimethylamino-2-chloromethylsaccharin. Alternatively, reaction of 4-dimethylaminosaccharin with paraformaldehyde and chlorotrimethylsilane in the presence of a catalytic amount of stannic chloride in ethylene dichloride affords 4-dimethylamino-2-chloromethylsaccharin.

Preparation 25

To a solution of 1.0 g (2.75 mm) 6-hydroxy-4-isopropyl-2-phenylthiomethylsaccharin in THF was added 0.73 g (2.78 mm) triphenylphosphine, 0.14 g (3.04 mm) ethanol and 0.48 g (2.76 mm) diethyl azodicarboxylate at RT. The mixture was stirred for 10-12 hr. The reaction was repeated starting with 3.73 g (10.28 mm) of the 6-hydroxy compound. The reaction mixtures were combined and then flash chromatographed on silica gel with ethyl acetate in hexane (10% followed by 15%) to give 4.37 g (85%) 6-ethoxy-4-isopropyl-2-phenylthiomethylsaccharin, mp 111.5-112.5°C, which was converted to 2-chloromethyl-6-ethoxy-4-iso-




propylsaccharin in 91% yield, mp 127-128°C, following the procedure of Preparation 18A.

Other 4-R₁-R₂-R₃-saccharins of formula IV useful as intermediates for the preparation of compounds of formula I can be prepared as follows.

Reaction of 2-trifluoromethylbenzoic acid with thionyl chloride affords 2-trifluoromethylbenzoyl chloride, which, on reaction with diethylamine, affords 2-trifluoromethyl-N,N-diethylbenzamide. Following a procedure similar to that described in Preparation 5, reaction of the latter with s-butyl lithium and reaction of the resulting lithium salt with sulfur dioxide followed by sodium hydroxylamine-O-sulfonate affords 2-trifluoromethyl-6-aminosulfonyl-N,N-diethyl benzamide, which, on heating in glacial acetic acid, affords 4-trifluoromethylsaccharin.

Similarly, reaction of 2-trichloromethylbenzoic acid with thionyl chloride affords 2-trichloromethylbenzoyl chloride, which, on reaction with diethylamine, affords 2-trichloromethyl-N,N-diethylbenzamide. Following a procedure similar to that described in Preparation 5, reaction of the latter with s-butyl lithium and reaction of the resulting lithium salt with sulfur dioxide followed by sodium hydroxylamine-O-sulfonate affords 2-trichloromethyl-6-aminosulfonyl-N,N-diethylbenzamide, which, on heating in glacial acetic acid, affords 4-trichloromethylsaccharin.


Reaction of 4-cyclohexylbenzoic acid with thionyl chloride affords 4-cyclohexylbenzoyl chloride, which, on reaction with diethylamine, affords 4-cyclohexyl-N,N-diethylbenzamide. Following a procedure similar to that described in Preparation 5, reaction of the latter with s-butyl lithium and reaction of the resulting lithium salt with sulfur dioxide followed by sodium hydroxylamine-O-sulfonate affords 4-cyclohexyl-2-aminosulfonyl-N,N-diethylbenzamide, which, on heating in glacial acetic acid, affords 6-cyclohexylsaccharin.



Benzylation of 6-nitrosaccharin affords 2-benzyl-6-nitrosaccharin which on reduction with stannous chloride and aqueous hydrogen chloride affords 2-benzyl-6-aminosaccharin. Reaction of the latter with methanesulfonyl chloride, trifluoromethylsulfonyl chloride or trichloromethylsulfonyl chloride in MDC in the presence of pyridine followed by transfer hydrogenolysis of the 2-benzyl protecting group affords, respectively, 6-methylsulfonylaminosaccharin, 6-trifluoromethylsulfonylaminosaccharin or 6-trichloromethylsulfonylaminosaccharin.

Diazotization of 6-aminosaccharin with nitrous acid in an acid medium and decomposition of the resulting diazonium salt in the presence of cupric cyanide or cupric chloride and sulfur dioxide, or cupric chloride and an alkali metal salt of methyl mercaptan or trifluoromethyl mercaptan affords, respectively, 6-cyanosaccharin, 6-chlorosulfonylsaccharin, 6-methylthiosaccharin or 6-trifluoromethylthiosaccharin. Reaction of the 6-chlorosulfonylsaccharin in situ with ammonia or methanesulfonylamide affords, respectively, 6-aminosulfonylsaccharin and 6-methanesulfonylamino-sulfonylsaccharin. Oxidation of 6-methylthiosaccharin and 6-trifluoromethylthiosaccharin with two molar equivalents of 3-chloroperbenzoic acid affords 6-methylsulfonylsaccharin and 6-trifluoromethylsulfonylsaccharin, respectively.

Hydrolysis of 6-cyanosaccharin by heating with aqueous sodium hydroxide affords saccharin-6-carboxylic acid. N-Benzylation of 6-cyanosaccharin affords 2-benzyl-6-cyanosaccharin. The latter on alkaline hydrolysis affords 2-benzylsaccharin-6-carboxylic acid which on conversion to 2-benzylsaccharin-6-carboxylic acid chloride by reaction with thionyl chloride followed by exhaustive hydrogenation over palladium-carbon affords 6-hydroxymethylsaccharin. Oxidation of the latter with pyridine:chromium trioxide (2:1) complex (Collins reagent) in MDC affords 6-formylsaccharin.




which on reductive amination with ammonia affords 6-amino-methylsaccharin.

5 Reaction of 4-trifluoromethylbenzoic acid with thionyl chloride affords 4-trifluoromethylbenzoyl chloride, which on reaction with diethylamine, affords 4-trifluoro-methyl-N,N-diethylbenzamide. Following a procedure similar to that described in Preparation 5, reaction of the latter with s-butyl lithium and reaction of the resulting lithium salt with sulfur dioxide followed by sodium hydroxylamine-O-sulfonate
10 affords 4-trifluoromethyl-2-aminosulfonyl-N,N-diethylbenzamide, which on heating in glacial acetic acid, affords 6-tri-fluoromethylsaccharin.

15 Reaction of 4-trichloromethylbenzoic acid with thionyl chloride affords 4-trichloromethylbenzoyl chloride, which, on reaction with diethylamine, affords 4-trichloro-methyl-N,N-diethylbenzamide. Following a procedure similar to that described in Preparation 5, reaction of the latter with s-butyl lithium and reaction of the resulting lithium salt with sulfur dioxide followed by sodium hydroxylamine-O-sulfonate
20 affords 4-trichloromethyl-2-aminosulfonyl-N,N-diethylbenzamide, which, on heating in glacial acetic acid, affords 6-tri-chloromethylsaccharin.

25 Reaction of 2-ethenylbenzoic acid with thionyl chloride affords 2-ethenylbenzoyl chloride, which on reaction with diethylamine, affords 2-ethenyl-N,N-diethylbenzamide. Reaction of the latter with s-butyl lithium and reaction of the resulting lithium salt with sulfur dioxide followed by sodium hydroxylamine-O-sulfonate affords 2-ethenyl-6-amino-sulfonyl-N,N-diethylbenzamide, which, on heating in glacial
30 acetic acid, affords 4-ethenylsaccharin.

 Reaction of 2-ethenyl-6-aminosulfonyl-N,N-diethylbenzamide with bromine affords 2-(1,2-dibromo-ethyl)-6-aminosulfonyl-N,N-diethylbenzamide which, on reaction with sodium amide in ammonia affords 2-ethynyl-



6-aminosulfonyl-N,N-diethylbenzamide, which, on heating in glacial acetic acid, affords 4-ethynylsaccharin.

5 Reaction of ethyl 2-aminobenzoate with two molar equivalents of benzyl chloride in acetone in the presence of potassium carbonate affords ethyl 2-(N,N-dibenzylamino)-benzoate which, on saponification in aqueous ethanolic potassium hydroxide and isolation of the product from a neutral medium, affords 2-(N,N-dibenzylamino)benzoic acid.

10 Reaction of the latter with thionyl chloride affords 2-(N,N-dibenzylamino)benzoyl chloride, which, on reaction with diethylamine, affords 2-(N,N-dibenzylamino)-N,N-diethylbenzamide. Reaction of the latter with s-butyl lithium and reaction of the resulting lithium salt with sulfur dioxide followed by sodium hydroxylamine-O-sulfonate
15 affords 2-(N,N-dibenzyl)-6-aminosulfonyl-N,N-diethylbenzamide, which, on heating in glacial acetic acid, affords 4-(N,N-dibenzylamino)saccharin which, on catalytic debenzylation with hydrogen over palladium-on-charcoal, affords 4-aminosaccharin. Reductive alkylation of the latter
20 with one molar equivalent of formaldehyde in formic acid affords 4-methylaminosaccharin.

Selective N-benylation of the cesium salt of 6-hydroxy-4-isopropylsaccharin (Preparation 19) with benzyl bromide and reaction of the 2-benzyl-6-hydroxy-4-isopropyl-
25 saccharin with N,N-diethylthiocarbamyl chloride in DMF using the procedure described above in Preparation 12 affords 2-benzyl-4-isopropyl-6-(N,N-diethylthiocarbamyloxy)-saccharin which, on heating, rearranges to 2-benzyl-4-isopropyl-6-(N,N-diethylcarbamylothio)saccharin. The latter, on
30 hydrolysis with alkali, affords 2-benzyl-4-isopropyl-6-mercaptosaccharin which on reaction with methyl iodide, and transfer hydrogenolysis affords 4-isopropyl-6-methylthiosaccharin. Oxidation of the latter with one or two molar equivalents of 3-chloroperbenzoic acid affords 4-isopropyl-



6-methylsulfinylsaccharin and 4-isopropyl-6-methyl-sulfonylsaccharin.

Reaction of 2-isopropyl-4-fluorobenzoic acid with thionyl chloride affords 2-isopropyl-4-fluorobenzoyl chloride, which, on reaction with diethylamine, affords 2-isopropyl-4-fluoro-N,N-diethylbenzamide. Reaction of the latter with s-butyl lithium and reaction of the resulting lithium salt with sulfur dioxide followed by sodium hydroxylamine-O-sulfonate affords 2-isopropyl-4-fluoro-2-aminosulfonyl-N,N-diethylbenzamide, which, on heating in glacial acetic acid, affords 4-isopropyl-6-fluorosaccharin.

Reaction of the latter with thiophenol, 4-methylphenylthiophenol, 4-methoxyphenylthiophenol, 4-chlorophenylthiophenol, 1-mercapto-4-methylnaphthalene or 1-mercaptanaphthalene by heating the reactants in DMF affords, respectively, 4-isopropyl-6-phenylthiosaccharin, 4-isopropyl-6-(4-methylphenylthio)saccharin, 4-isopropyl-6-(4-methoxy-phenylthio)saccharin, 4-isopropyl-6-(4-chlorophenylthio)-saccharin, 4-isopropyl-6-(4-methyl-1-naphthylthio)saccharin and 4-isopropyl-6-(1-naphthylthio)saccharin, oxidation of which in each case with one or two molar equivalents of 3-chloroperbenzoic acid affords 4-isopropyl-6-phenylsulfinyl-saccharin, 4-isopropyl-6-phenylsulfonylsaccharin, 4-isopropyl-6-(4-methylphenylsulfinyl)-saccharin, 4-isopropyl-6-(4-methylphenylsulfonyl)saccharin, 4-isopropyl-6-(4-methoxy-phenylsulfinyl)saccharin, 4-isopropyl-6-(4-methoxyphenyl-sulfonyl)saccharin, 4-isopropyl-6-(4-chlorophenylsulfinyl)-saccharin, 4-isopropyl-6-(4-chlorophenylsulfonyl)saccharin, 4-isopropyl-6-(4-methyl-1-naphthylsulfinyl)saccharin, 4-isopropyl-6-(4-methyl-1-naphthylsulfonyl)saccharin, 4-isopropyl-6-(1-naphthylsulfinyl)saccharin and 4-isopropyl-6-(1-naphthylsulfonyl)-saccharin.

Reaction of 2-benzyl-6-hydroxy-4-isopropyl-saccharin with one molar equivalent of acetic anhydride,



benzoyl chloride or 1-naphthylcarboxylic acid chloride followed in each case by transfer hydrogenolysis affords, respectively, 4-isopropyl-6-acetoxysaccharin, 4-isopropyl-6-benzoyloxy-saccharin and 4-isopropyl-6-(1-naphthyl-carbonyloxy)-saccharin.

Heating 4-isopropyl-6-fluorosaccharin in DMF with azetidine, pyrrolidine, piperidine, morpholine, 1-benzyl piperazine, 1-methylpiperazine, imidazole, t-butyl alpha-aminoacetate or ammonia affords, respectively, 4-isopropyl-6-(1-azetidiny)saccharin, 4-isopropyl-6-(1-pyrrolidinyl)-saccharin, 4-isopropyl-6-(1-piperidinyl)saccharin, 4-isopropyl-6-(4-morpholinyl)saccharin, 4-isopropyl-6-(4-benzyl-1-piperazinyl)saccharin, 4-isopropyl-6-(4-methyl-1-piperazinyl)saccharin, 4-isopropyl-6-(1-1H-imidazolyl)-saccharin, 4-isopropyl-6-(t-butoxycarbonylmethylamino)-saccharin and 4-isopropyl-6-aminosaccharin.

Catalytic debenzylation of 4-isopropyl-6-(4-benzyl-1-piperazinyl)saccharin with hydrogen over palladium-on-charcoal affords 4-isopropyl-6-(1-piperazinyl)-saccharin.

Hydrolysis of 4-isopropyl-6-(t-butoxycarbonylmethylamino)saccharin with dilute hydrochloric acid and isolation of the product from a neutral medium affords 4-isopropyl-6-carboxymethylaminosaccharin.

Reaction of 4-isopropyl-6-aminosaccharin with one molar equivalent of acetyl chloride affords 4-isopropyl-6-acetylaminosaccharin.

Saponification of 4-carbomethoxysaccharin (Preparation 9D) to the corresponding saccharin-4-carboxylic acid by alkaline hydrolysis, conversion of the acid to the corresponding acid chloride by reaction of the acid with thionyl chloride and reaction of the acid chloride with ammonia affords saccharin-4-carboxamide.

Diazotization of aminosaccharin with nitrous acid in an acid medium and decomposition of the resulting diazonium



salt in the presence of cupric cyanide affords 4-cyano-saccharin.

- 5 The 4-R₁-R₂-R₃-2-chloromethylsaccharins of formula VI listed in TABLE B where, in each instance, R₃ is hydrogen and X is Cl, can be prepared by reaction of the 4-R₁-R₂-R₃-saccharins so-prepared with chloromethylphenyl sulfide in the presence of potassium t-butoxide and tetra-butylammonium bromide, followed by reaction of the resulting 4-R₁-R₂-R₃-2-phenylthiomethylsaccharins with sulfuryl
- 10 chloride in MDC; and/or by reaction of the 4-R₁-R₂-R₃-saccharins so prepared with paraformaldehyde and chlorotrimethylsilane in the presence of a catalytic amount of stannic chloride in ethylene dichloride.

This Sheet Has Been Replaced




TABLE B

<u>Preparation</u>	<u>R₁</u>	<u>R₂</u>
26	CF ₃	H
27	CCl ₃	H
28	H	6-cyclohexyl
29	H	6-CH ₃ SO ₂ NH
30	H	6-CF ₃ SO ₂ NH
31	H	6-CCl ₃ SO ₂ NH
32	H	6-CN
33	H	6-CONH ₂
34	H	6-NH ₂ SO ₂
35	H	6-CH ₃ SO ₂ NHSO ₂
36	H	6-CH ₃ SO ₂
37	H	6-CF ₃ SO ₂
38	H	6-HOOC
39	H	6-HOCH ₂
40	H	6-OHC
41	H	6-NH ₂ CH ₂
42	H	6-CF ₃
43	H	6-CCl ₃
44	CH=CH ₂	H
45	C≡CH	H
46	NH ₂	H
47	CH ₃ NH	H
48	CH(CH ₃) ₂	6-CH ₃ S
49	CH(CH ₃) ₂	6-CH ₃ SO
50	CH(CH ₃) ₂	6-CH ₃ SO ₂
51	CH(CH ₃) ₂	6-F
52	CH(CH ₃) ₂	6-C ₆ H ₅ S
53	CH(CH ₃) ₂	6-(4-CH ₃ C ₆ H ₄ S)
54	CH(CH ₃) ₂	6-(4-CH ₃ OC ₆ H ₄ S)
55	CH(CH ₃) ₂	6-(4-ClC ₆ H ₄ S)
56	CH(CH ₃) ₂	6-(4-CH ₃ -1-naphthyl-S)

This Sheet Has Been Replaced




TABLE B (contd.)

Preparation	R ₁	R ₂
57	CH(CH ₃) ₂	6-(1-naphthyl-S)
58	CH(CH ₃) ₂	6-C ₆ H ₅ SO
59	CH(CH ₃) ₂	6-C ₆ H ₅ SO ₂
60	CH(CH ₃) ₂	6-(4-CH ₃ C ₆ H ₄ SO)
61	CH(CH ₃) ₂	6-(4-CH ₃ C ₆ H ₄ SO ₂)
62	CH(CH ₃) ₂	6-(4-CH ₃ OC ₆ H ₄ SO)
63	CH(CH ₃) ₂	6-(4-CH ₃ OC ₆ H ₄ SO ₂)
64	CH(CH ₃) ₂	6-(4-ClC ₆ H ₄ SO)
65	CH(CH ₃) ₂	6-(4-ClC ₆ H ₄ SO ₂)
66	CH(CH ₃) ₂	6-(4-CH ₃ -1-naphthyl-SO)
67	CH(CH ₃) ₂	6-(4-CH ₃ -1-naphthyl-SO ₂)
68	CH(CH ₃) ₂	6-(1-naphthyl-SO)
69	CH(CH ₃) ₂	6-(1-naphthyl-SO ₂)
70	CH(CH ₃) ₂	6-CH ₃ COO
71	CH(CH ₃) ₂	6-C ₆ H ₅ COO
72	CH(CH ₃) ₂	6-(1-naphthyl-COO)
73	CH(CH ₃) ₂	6-(1-azetidinyI)
74	CH(CH ₃) ₂	6-(1-pyrrolidinyl)
75	CH(CH ₃) ₂	6-(1-piperidinyl)
76	CH(CH ₃) ₂	6-(4-morpholinyl)
77	CH(CH ₃) ₂	6-(4-benzyl-1-piperazinyl)
78	CH(CH ₃) ₂	6-(4-methyl-1-piperazinyl)
79	CH(CH ₃) ₂	6-(1-1H-imidazolyl)
80	CH(CH ₃) ₂	6-(NHCH ₂ COOC ₄ H ₉ -t)
81	CH(CH ₃) ₂	6-NH ₂
82	CH(CH ₃) ₂	6-(1-piperazinyl)
83	CH(CH ₃) ₂	6-(NHCH ₂ COOH)
84	CH(CH ₃) ₂	6-(CH ₃ CONH)
85	CONH ₂	H
86	CN	H



Preparation 87

Reaction of isothiazole-5-carboxaldehyde with lithium 3-(triphenylphosphoranylidene)propanoate under standard Wittig conditions provides 4-(5-isothiazolyl)-
5 3-butenic acid which is reduced and cyclized with aluminum chloride to provide 4-oxo-4,5,6,7-tetrahydro-1,2-benzisothiazole. The 4-oxo compound is reacted with methylenetriphenyl phosphorane under standard Wittig conditions and a methylene is inserted into the resulting
10 4-methylene compound via a Simmons Smith reaction to provide 6,7-dihydrospiro[1,2-benzisothiazole-4(5H),1'-cyclopropane] which is oxidized with hydrogen peroxide in acetic acid to give 6,7-dihydrospiro[3-oxo-1,2-benzisothiazole-4(5H),1'-cyclopropane 1,1-dioxide]
15 (4-spirocyclopropyl-4,5,6,7-tetrahydrosaccharin). The latter is chloromethylated according to the procedure of Preparation 1 to give 2-chloromethyl-4-spirocyclopropyl-4,5,6,7-tetrahydrosaccharin.

Preparation 88

20 2-Benzyl-4-isopropyl-6-oxotetrahydrosaccharin of Preparation 21 is reduced with sodium borohydride and methylated with methyl iodide in the presence of sodium hydride to afford 2-benzyl-4-isopropyl-6-methoxytetrahydrosaccharin. This is debenzylated and chloromethylated as in
25 Preparation 21 to provide 2-chloromethyl-4-isopropyl-6-methoxy-4,5,6,7-tetrahydrosaccharin.

Preparation 89

To freshly distilled cyclopentadiene (25 ml) at 0°C was added 4-bromo-2-(tert-butyl)isothiazol-3(2H)-one
30 1,1-dioxide (Helv. Chim. Acta, 72, 1416, 1989) (7.9 g, 0.03 mol). After stirring at 0°C under nitrogen for 16 hr, the reaction mixture was concentrated in vacuo. The residue was purified by filtering through silica gel, eluting with hexanes (500 ml) followed by 20% ethyl acetate in hexanes (500 ml)
35 followed by 20% ethyl acetate in hexanes (500 ml). The



eluates were concentrated in vacuo to give 9.8 g (100%) of the norbornene adduct, 3a-bromo-2-t-butyl-3a,4,7,7a-tetrahydro-4,7-methano-1,2-benzisothiazol-3(2H)-one 1,1-dioxide, as a white solid.

- 5 The adduct (0.4 g, 1.2 mmol) in 25 ml ethyl acetate containing 5% Pd on CaCO₃ (0.2 g) was stirred under one atmosphere of hydrogen for 4 hr, and the reaction mixture was filtered through a pad of silica gel, eluting with ethyl acetate (100 ml). The eluates were concentrated in vacuo and
10 the residue crystallized from hexanes to give 0.4 g (100%) of the bromo norbornane, 3a-bromo-2-t-butyl-3a,4,5,6,7,7a-hexahydro-4,7-methano-1,2-benzisothiazol-3(2H)-one 1,1-dioxide, as a white crystalline solid.

- To a solution of the bromo norbornane (3.7 g,
15 0.011 mol) in toluene (25 ml) at 0°C was added diazabicyclononene (1.37 g, 0.011 mol) in toluene (10 ml). After stirring at 0°C for 20 min, silica gel (25 g) was added to the reaction mixture. The resulting slurry was loaded on top of a 15 cm pad of silica gel and eluted with 20% ethyl acetate in hexanes
20 (800 ml). The eluates were concentrated in vacuo to give 2.8 g (100%) of the dehydrobrominated compound, 2-t-butyl-4,5,6,7-tetrahydro-4,7-methano-1,2-benzisothiazol-3(2H)-one 1,1-dioxide, as a white solid.

- The dehydrobrominated compound (2.8 g,
25 0.011 mol) in trifluoroacetic acid (30 ml) was heated at reflux for 48 hr and let stand at room temperature for 4 days. The resulting mixture was concentrated in vacuo, treated with methanol (20 ml) and evaporated to dryness. The residue was taken up in ether (100 ml) and washed with saturated NaHCO₃
30 (1 x 50 ml). The layers were separated and the aqueous phase acidified to pH 1 with 2N HCl and extracted with MDC (2 x 100 ml). The combined organic extracts were dried and concentrated in vacuo to give 0.9 g (42%) of the bicyclo-(2.2.1)saccharin derivative, 4,5,6,7-tetrahydro-4,7-methano-



1,2-benzisothiazol-3(2H)-one 1,1-dioxide (4,5,6,7-tetrahydro-4,7-methano-saccharin), as a white solid.

A mixture of the bicyclo(2.2.1)saccharin derivative (0.9 g, 5 mmol), chloromethyl phenylsulfide (0.07 g, 7 mmol) and tetrabutylammonium bromide (0.36 g, 0.16 mmol) in toluene (50 ml) was refluxed under nitrogen for 16 hr, cooled to room temperature and evaporated to dryness under vacuum. The residue was purified by flash chromatography on silica gel (100 g) using 100% MDC as the eluant to give 1.05 g (72%) of the corresponding 2-phenylthiomethyl derivative as a viscous oil.

The latter (1.05 g, 3 mmol) in dichloromethane (100 ml) was treated with sulfur chloride (0.66 g, 5 mmol) and stirred for 2 hr. The resulting yellow solution was diluted with MDC (100 ml), washed with saturated NaHCO₃ solution, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (33% MDC in hexanes) to give 0.66 g (81%) of 2-chloromethyl-4,5,6,7-tetrahydro-4,7-methano-1,2-benzisothiazol-3(2H)-one 1,1-dioxide (2-chloromethyl-4,5,6,7-tetrahydro-4,7-methanosaccharin).
Preparations 90 and 91

By processes analogous to those of Preparation 89, it is contemplated that cyclohexadiene or 1,1-dimethylcyclopentadiene can be reacted with 4-bromo-2-(tert-butyl)-isothiazol-3(2H)-one 1,1-dioxide to give, respectively, 3a-bromo-2-t-butyl-3a,4,7,7a-tetrahydro-4,7-ethano(or 4,7-di-methylmethano)-1,2-benzisothiazol-3(2H)-one 1,1-dioxide which can be hydrogenated to give 3a-bromo-2-t-butyl-3a,4,5,6,7,7a-hexahydro-4,7-ethano (or 4,7-dimethylmethano)-1,2-benzisothiazol-3(2H)-one 1,1-dioxide which can be dehydrobrominated to give 2-t-butyl-4,5,6,7-tetrahydro-4,7-ethano (or 4,7-dimethylmethano)-1,2-benzisothiazol-3(2H)-one 1,1-dioxide which can be dealkylated to give 4,5,6,7-tetrahydro-4,7-ethano(or 4,7-dimethylmethano)-1,2-benziso-



thiazol-3(2H)-one 1,1-dioxide which can be reacted with
chloromethyl phenylsulfide to give 2-phenylthiomethyl-
4,5,6,7-tetrahydro-4,7-ethano (or 4,7-dimethylmethano)-
1,2-benzisothiazol-3(2H)-one 1,1-dioxide which can be
5 reacted with sulfuryl chloride to give 2-chloromethyl-
4,5,6,7-tetrahydro-4,7-ethano (or 4,7-dimethylmethano)-
1,2-benzisothiazol-3(2H)-one, i.e., 2-chloromethyl-
4,5,6,7-tetrahydro-4,7-ethanosaccharin (Prep. 90) or
2-chloromethyl-4,5,6,7-tetrahydro-4,7-dimethylmethano-
10 saccharin (Prep. 91).

Preparations 92E - 94E

General procedure for the preparation of methyl 2-alkylcyclo-
hexan-6-onecarboxylate:

To a suspension of anhydrous CuI (10 mmol) in
15 anhydrous THF (100 ml) was added Me₂S (100 mmol) and the
resulting solution was cooled to -78°C. The Grignard reagent
(alkyl magnesium bromide) (20 mmol) was added over a
period of 15 min. After being stirred at -78°C for an hour, a
solution of cyclohexenone (10 mmol) in THF was added and
20 stirring continued for another 15 min. To the resulting
mixture was added HMPA (5 ml) and, after 15 min, methyl
cycloformate (30 mmol) in THF (20 ml) and the reaction
warmed to room temperature and stirred overnight. The
reaction mixture was quenched with 2N HCl (50 ml). The
25 layers were separated and the aqueous phase extracted with
Et₂O (1 x 100 ml). The combined organic extracts were
washed with saturated NH₄Cl solution (3 x 50 ml), water
(2 x 50 ml), brine (1 x 50 ml) and dried (Na₂SO₄). Removal of
the solvent in vacuo and purification by either Kugelrohr
30 distillation or flash chromatography afforded the desired
methyl 2-alkylcyclohexan-6-onecarboxylate (TABLE C).




TABLE C

Intermediate	Alkyl	Yield(%)	b.p.
92A	Me	82	--
93A	Et	70	100-110°C (0.2 mm)
94A	i-Pr	74	106-109°C (0.5 mm)

General procedure for the preparation of methyl 2-benzylthio-6-alkylcyclohex-2-enecarboxylate and methyl 2-benzylthio-6-alkylcyclohex-1-enecarboxylate:

5 A mixture of methyl 2-alkyl-cyclohexan-6-one-carboxylate (1 eq), benzylmercaptan (1.1 eq) and the acidic clay montmorillonite, KSF (1.5 times the weight of methyl 2-alkylcyclohexan-6-onecarboxylate) in anhydrous toluene (50-100 ml) was refluxed under nitrogen with azeotropic
10 removal of water for 12-14 hr and cooled to room temperature. The solids were filtered off and washed with ether. The combined filtrate was washed with 10% Na₂CO₃, water, brine and dried. Removal of the solvent in vacuo and purification of the residue by flash chromatography on silica
15 gel (10% ether in hexanes) gave a mixture of methyl 2-benzylthio-6-alkylcyclohex-2-enecarboxylate and methyl 2-benzylthio-6-alkylcyclohex-1-enecarboxylate (TABLE D) which was used in the next step as a mixture.

TABLE D

Intermediate	Alkyl	Combined Yield of Mixture(%)
92B	Me	44
93B	Et	50
94B	i-Pr	52

20 General procedure for the preparation of 4-alkyltetrahydro-saccharins:

A solution of methyl 2-benzylthio-6-alkylcyclohex-2-enecarboxylate and methyl 2-benzylthio-6-alkylcyclohex-1-enecarboxylate (1-10 mmol of the mixture) in 10 ml MDC
25 was diluted with 20-50 ml glacial acetic acid and




1-5 ml water, the mixture cooled to -10°C , and chlorine gas was bubbled through the mixture until the exothermic reaction subsided. The mixture was then stirred for 10 min and taken to dryness to give a mixture of methyl 2-chlorosulfonyl-6-alkylcyclohex-2-enecarboxylate and methyl 2-chlorosulfonyl-6-alkylcyclohex-1-enecarboxylate, which was dissolved in 10 ml THF and added to 25 ml of a solution of concentrated ammonium hydroxide while cooling in an ice/acetone bath. After stirring for 2 hr, the reaction mixture was concentrated in vacuo, the residue taken up in water, acidified to pH 1 with 2N HCl, and extracted with MDC. The organic phase was dried and concentrated in vacuo to give a mixture of methyl 2-aminosulfonyl-6-alkylcyclohex-2-enecarboxylate and methyl 2-aminosulfonyl-6-alkylcyclohex-1-enecarboxylate. The mixture was dissolved in methanol and added to a freshly prepared solution of sodium methoxide (10-50 mmol) and stirred at ambient temperature for 12 hr. The reaction mixture was concentrated in vacuo, diluted with water and extracted with ether. The organic phase was discarded, and the aqueous phase was acidified to pH 1 with concentrated HCl and extracted with MDC. The organic extracts, on washing with brine, drying and evaporation to dryness, afforded 4-alkyl-4,5,6,7-tetrahydro-1,2-benzisothiazol-3(2H)-one 1,1-dioxide (4-alkyl-4,5,6,7-tetrahydro-saccharin) (TABLE E).

TABLE E

Intermediate	Alkyl	Yield(%)
92C	Me	85
93C	Et	80
94C	i-Pr	74

This Sheet Has Been Replaced



A mixture of 4-alkyl-4,5,6,7-tetrahydro-1,2-benzisothiazol-3(2H)-one 1,1-dioxide (4-alkyl-4,5,6,7-tetrahydrosaccharin) (1.0 eq), chloromethyl phenyl sulfide (1.5 eq) and tetrabutylammonium bromide (0.2 eq) in toluene

(25 ml/g saccharin) was refluxed under nitrogen for 16-24 hr and then cooled to room temperature. The resulting mixture was evaporated to dryness and the residue chromatographed on silica gel eluting with hexanes/MDC (1:1 to 1:3) to give the corresponding 2-phenylthiomethyl-4-alkyl-4,5,6,7-tetrahydro-1,2-benzisothiazol-3(2H)-one 1,1-dioxide (2-phenylthiomethyl-4-alkyl-4,5,6,7-tetrahydrosaccharin) (TABLE F).

TABLE F

Intermediate	Alkyl	Yield(%)
92D	Me	55
93D	Et	40
94D	i-Pr	53

A solution of 2-phenylthiomethyl-4-alkyl-4,5,6,7-tetrahydrosaccharin (1.0 eq) was treated with sulfur chloride (1.5 eq) and stirred for 2 hr. The resulting yellow solution was taken to dryness to give the 2-chloromethyl-4-alkyl-4,5,6,7-tetrahydrosaccharin. The compounds prepared are those wherein alkyl is Me (92E), Et (93E) and i-Pr (94E).

Preparation 95

By following the general procedure described for Preparations 92B-94B to 92E-94E and starting with methyl cyclohexan-6-onecarboxylate, there was obtained, successively, a mixture of methyl 2-benzylthiocyclohex-1(and 2)-ene-carboxylate (40% yield), a mixture of methyl 2-chlorosulfonyl-cyclohex-1(and 2)-enecarboxylate, a mixture of methyl 2-aminosulfonylcyclohex-1(and 2)-enecarboxylate, 4,5,6,7-tetrahydro-1,2-benzisothiazol-3(2H)-one 1,1-dioxide (4,5,6,7-tetrahydrosaccharin) (50% yield), 2-phenylthiomethyl-4,5,6,7-tetrahydro-1,2-benzisothiazol-3(2H)-one



1,1-dioxide (2-phenylthiomethyl-4,5,6,7-tetrahydrosaccharin) (40% yield) and 2-chloromethyl-4,5,6,7-tetrahydro-1,2-benz-isothiazol-3(2H)-one 1,1-dioxide (2-chloromethyl-4,5,6,7-tetrahydrosaccharin).

5 Preparation 96

Methyl 2,2-dimethylcyclohexan-6-one carboxylate:

To a suspension of anhydrous CuI (70.0 g, 0.37 mol) in anhydrous ether (500 ml) at 0°C was added halide-free methyl lithium (520 ml or 1.4 M solution in ether, 10 0.73 mol). After being stirred at 0°C for 15 min, a solution of 3-methyl-2-cyclohexenone (20.0 g, 0.18 mol) in ether (50 ml) was added and stirring continued for another 1 hr. To the resulting mixture was added THF (50 ml) and HMPA (25 ml) and after 15 min methyl cyanoformate (45.0 g, 0.53 mol) in 15 THF (20 ml) and the reaction warmed to room temperature and stirred for 3 hr. The reaction mixture was quenched with 2N HCl (50 ml). The layers were separated and the aqueous phase extracted with Et₂O (1 x 500 ml). The combined organic extracts were washed with saturated NH₄Cl solution 20 (3 x 50 ml), water (2 x 50 ml), brine (1 x 50 ml) and dried (Na₂SO₄). Removal of the solvent in vacuo and purification by Kugelrohr distillation afforded 34.0 g (99%) of methyl 2,2-di- methylcyclohexan-6-one carboxylate, bp 80-84°C/0.6 mm, which was converted to 2-chloromethyl-4,4-dimethyl- 25 4,5,6,7-tetrahydrosaccharin following the general procedures described above for Preparations 92B-94B to 92E-94E.

Preparation of the End-Products

Example 1

A solution of 2-bromomethylsaccharin (2.0 g, 7.2 mmol), dibutyl phosphate (2.29 g, 10.9 mmol) and 30 N,N-diisopropylethylamine (1.41 g, 10.9 mmol) in 40 ml methylene dichloride was stirred at room temperature for 48 hr. The reaction mixture was concentrated and the residue flash chromatographed on silica gel eluting with 30% 35 ethyl acetate in hexanes to give 2.35 g (80%) of dibutyl



2-saccharinylmethyl phosphate as a colorless oil.

Example 2

A solution of 2-chloromethyl-4-ethoxysaccharin (2.0 g, 7.3 mmol), diethyl phosphate (1.68 g, 10.9 mmol), and triethylamine (1.53 ml, 10.9 mmol) in 25 ml methylene dichloride was refluxed for 58 hr. On cooling, the reaction mixture was concentrated and the residue flash chromatographed on silica gel eluting with ethyl acetate-hexanes to give 2.0 g (73%) of diethyl 4-ethoxy-2-saccharinyl-methyl phosphate as a colorless oil.

Example 3

To a solution of dibenzyl phosphate (0.69 g, 2.48 mmol) in 30 ml methanol at room temperature was added cesium carbonate (0.403 g, 1.24 mmol). After stirring for 2 hr, the solvent was evaporated and the residue was dried under high vacuum and suspended in 10 ml N,N-dimethylformamide. To the suspension was added 2-chloromethyl-4-isopropyl-6-methoxysaccharin (0.5 g, 1.6 mmol) and the mixture stirred at 50°C in an oil bath for 24 hr. On cooling, the mixture was diluted with ice-water and extracted with 200 ml ether-ethyl acetate (4:1). The organic layer was separated and washed successively with water and then saturated brine. The extract was dried over magnesium sulfate, filtered, concentrated, and the residue was flash chromatographed on silica gel eluting with ethyl acetate-hexanes to give 0.46 g (52%) of dibenzyl 4-isopropyl-6-methoxy-2-saccharinylmethyl phosphate as an oil which crystallized on standing, mp 75.5-76.5°C.

Following procedures similar to those described in Examples 1, 2 and 3 above (Methods 1, 2 and 3 respectively hereafter), the compounds of Formula I listed in TABLE 1 below were similarly prepared. In each of Examples 4-9 the products were prepared from 2-bromomethylsaccharin. In Examples 10-21 the products were prepared from the corresponding 2-chloromethylsaccharin.



Example	R ₁	R ₂ /R ₃	m=n=	A = B =	Method	mp(°C)	Yield(%)
4	H	H/H	1	CH ₂ Ph	1	oil	39
5	H	H/H	1	CH ₃	1	oil	20
6	H	H/H	1	CH ₂ CH ₃	1	oil	71
7	H	H/H	1	Ph	1	oil	24
8	H	H/H	0	Ph	1	128.5-129.5	75
9	H	H/H	0	C ₆ H ₄ -4-(OCH ₃)	1	foam	88
10	CH(CH ₃) ₂	H/H	1	CH ₂ CH ₃	2	oil	83
11	OCH ₃	6-OCH ₃ /H	1	CH ₂ CH ₃	2	110.0-111.0	63
12	CH(CH ₃) (CH ₂ CH ₃)	H/H	1	CH ₂ CH ₃	2	oil	25
13	CH(CH ₃) ₂	6-OCH ₃ /H	1	CH ₂ CH ₃	2	oil	66
14	CH(CH ₃) ₂	H/H	0	Ph	2	137.5-138.5	53
15	CH(CH ₃) ₂	6-OCH ₃ /H	0	Ph	2	foam	78
16	CH(CH ₃) ₂	H/H	1	CH ₂ Ph	1	oil	37
17	CH(CH ₃) ₂	6-OH/H	1	CH ₂ CH ₃	3	127.5-128.5	23
18	CH(CH ₃) ₂	6-OCH ₃ /H	1	CH(CH ₃) ₂	3	101.5-102.5	57
19	CH(CH ₃) ₂	6-OCH ₂ CH ₃ /H	1	CH(CH ₃) ₂	3	96.0-97.0	66
20	CH(CH ₃) ₂	6-OCH ₃ /H	0	(CH ₂) ₃ CH ₃	3	oil	52
21	CH(CH ₃) ₂	6-OH/H	1	CH(CH ₃) ₂	3	123-125	58

This Sheet Has Been Replaced



The phosphate and phosphinic acid starting materials employed in the preparation of the compounds of Examples 1-17 and 20 are commercially available. Diisopropyl phosphate used in Examples 18, 19 and 21 was prepared as follows:

A mixture of diisopropyl chlorophosphate (10 g, 50 mmol) (reference: R.A. McIvor et al., Can. J. Chem. 34, 1819 (1956)) in 100 ml distilled water was stirred at 80°C in an oil bath for 2 hr. The mixture was concentrated under vacuum and the residual water was removed by azeotropic distillation with benzene (3 x 100 ml). After drying under high vacuum, 8.8 g (97%) of diisopropyl phosphate was obtained as an oil and used without purification.

Example 22

Diisopropyl 6-(2,2-dimethyl-1,3-dioxolan-4-yl)-methoxy-4-isopropyl-2-saccharinylmethyl phosphate:

Diethyl azodicarboxylate (0.96 g, 5.55 mmol) was added to a mixture of diisopropyl 6-hydroxy-4-isopropyl-2-saccharinylmethyl phosphate (2.37 g, 5.44 mmol), triphenylphosphine (1.44 g, 5.5 mmol) and glycerol dimethylketal (2,2-dimethyl-1,3-dioxolane-4-methanol) (0.79 g, 5.98 mmol) in 40 ml THF and the mixture was stirred for 15 hr at RT. Excess solvent was removed under reduced pressure and the residue was flash chromatographed (SiO₂; ethyl acetate-MDC) to give a first fraction yielding 0.49 g (19.7%) of the title compound as a thick oil, and a second fraction yielding 2.0 g of a mixture containing about 85% of the title compound.

Example 23

2-Saccharinylmethyl phosphate:

Dibenzyl 2-saccharinylmethyl phosphate (1.1 g), dissolved in 50 ml methanol, was subjected to hydrogenation over 10% Pd-C (0.3 g) at normal pressure for approximately 6 hr. The solution was concentrated under reduced pressure to give 2-saccharinylmethyl phosphate as a thick oily residue which was dissolved in methanol and treated with



cyclohexylamine (0.59 ml). On standing at RT crystals of the salt separated which were collected by filtration, washed with methanol-ether and dried to give 0.503 g (43.9%) of the di-cyclohexylamine salt of the title compound;
5 mp (shrinks at 214-215°C).


Example 24

a) Methyl 2,2-dimethylcyclohexan-6-onecarboxylate:


To a suspension of anhydrous CuI (70.0 g, 0.37 mol) in anhydrous ether (500 ml) at 0°C was added
10 halide-free methyl lithium (520 ml 1.4 M solution in ether, 0.73 mol). After being stirred at 0°C for 15 min, a solution of 3-methyl-2-cyclohexen-1-one (20.0 g, 0.18 mol) in ether (50 ml) was added and stirring was continued for 1 hr. To the resulting mixture was added THF (50 ml) and HMPA
15 (25 ml) and after 15 min methyl cyanoformate (45.0 g, 0.53 mol) in THF (20 ml) and the reaction warmed to room temperature and stirred for 3 hr. The reaction mixture was quenched with 2N HCl (50 ml). The layers were separated and the aqueous phase extracted with Et₂O (1 x 500 ml). The
20 combined organic extracts were washed with saturated NH₄Cl solution (3 x 50 ml), H₂O (2 x 50 ml), brine (1 x 50 ml) and dried (Na₂SO₄). Removal of the solvent in vacuo and purification by Kugelrohr distillation afforded 34.0 g (99%) of methyl 2,2-dimethylcyclohexan-6-onecarboxylate,
25 b.p.0.6 80-84°C.

b) Methyl 2-benzylthio-6,6-dimethylcyclohex-2-ene-carboxylate and methyl 2-benzylthio-6,6-dimethylcyclohex-1-enecarboxylate:

Amberlyst-15 acidic resin (25.0 g) was mixed with
30 polyphosphoric acid (3.0 g) and phosphoric acid (3.0 g) and heated under vacuum at 60°C for 2 hr. The resulting resin was mixed with methyl 2,2-dimethylcyclohexan-6-onecarboxylate (34.0 g, 0.18 mol), benzyl mercaptan (50.0 g, 0.40 mol) and powdered sieves 4Å (20.0 g) in anhydrous dichloro-



ethane (700 ml) and heated at reflux under nitrogen for 18 hr and cooled to room temperature. The solids were filtered off, the filtrate concentrated in vacuo and excess benzyl mercaptan distilled off. The pot residue was purified by chromatography (2:1/MDC:hexanes) to give 11.3 g (21%) of a mixture of methyl 2-benzylthio-6,6-dimethylcyclohexen-2-enecarboxylate and methyl 2-benzylthio-6,6-dimethylcyclohex-1-enecarboxylate.
c) The latter mixture (11.3 g, 0.04 mol) was dissolved in MDC (25 ml), diluted with glacial acetic acid (65 ml), water (10 ml), cooled to -10°C, and chlorine gas was bubbled through the mixture until the exothermic reaction subsided. The mixture was then stirred for 10 min and taken to dryness to give a mixture of methyl 2-chlorosulfonyl-6,6-dimethylcyclohexen-2-enecarboxylate and methyl 2-chlorosulfonyl-6,6-dimethylcyclohex-1-enecarboxylate, which was dissolved in 10 ml THF and added to 25 ml of a solution of conc. ammonium hydroxide while cooling in an ice/acetone bath. After stirring for 2 hr, the reaction mixture was concentrated in vacuo, the residue taken up in water, acidified to pH 1 with 2N HCl, and extracted with MDC. The organic phase was dried and concentrated in vacuo to give a mixture of methyl 2-aminosulfonyl-6,6-dimethylcyclohex-2-enecarboxylate and methyl 2-aminosulfonyl-6,6-dimethylcyclohex-1-enecarboxylate. The latter mixture was dissolved in methanol (25 ml) and added to a freshly prepared solution of sodium methoxide (0.20 mol) and stirred at ambient temperature for 12 hr. The reaction mixture was concentrated in vacuo, diluted with water and extracted with ether. The organic phase was discarded, and the aqueous phase acidified to pH 1 with concentrated HCl and extracted with MDC. The organic extracts, on washing with brine, drying and evaporation to dryness, afforded 3.5 g (42%) of 4,4-dimethyl-4,5,6,7-tetrahydro-1,2-benzisothiazol-3(2H)-one 1,1-dioxide (4,4-dimethyl-4,5,6,7-tetrahydrosaccharin).



- d) A mixture of 4,4-dimethyl-4,5,6,7-tetrahydro-1,2-benzisothiazol-3(2H)-one 1,1-dioxide (1.0 g, 4.7 mmol), chloromethyl phenyl sulfide (1.1 g, 7.0 mmol) and tetrabutyl ammonium bromide (0.3 g, 0.93 mmol) in toluene (25 ml) was refluxed under nitrogen for 16-24 hr and then cooled to room temperature. The resulting mixture was evaporated to dryness and the residue chromatographed on silica gel eluting with hexanes/MDC (1:1 to 1:3) to give 1.0 g (67%) of 2-phenylthiomethyl-4,4-dimethyl-4,5,6,7-tetrahydro-1,2-benzisothiazol-3(2H)-one 1,1-dioxide (2-phenylthiomethyl-4,4-dimethyl-4,5,6,7-tetrahydrosaccharin).
- e) A solution of 2-phenylthiomethyl-4,4-dimethyl-4,5,6,7-tetrahydro-1,2-benzisothiazol-3(2H)-one 1,1-dioxide (0.8 g, 2.4 mmol) was treated with sulfur chloride (0.48 g, 3.5 mmol) and stirred for 2 hr. The resulting yellow solution was taken to dryness, diluted with ether (100 ml) and washed with saturated NaHCO₃ and brine. The organic phase was dried and concentrated in vacuo to give 0.6 g (95%) of 2-chloromethyl-4,4-dimethyl-4,5,6,7-tetrahydro-1,2-benzisothiazol-3(2H)-one 1,1-dioxide (2-chloromethyl-4,4-dimethyl-4,5,6,7-tetrahydrosaccharin), which was treated with diethyl phosphate (1.05 g, 6.8 mmol) and triethylamine (0.7 g, 6.9 mmol) in dichloroethane (15 ml) at 50°C for 16 hr and cooled to room temperature. The resulting mixture was taken to dryness and purified by flash chromatography on silica gel (40% hexanes in ethyl acetate) to give 0.18 g (21%) of diethyl 4,4-dimethyl-4,5,6,7-tetrahydro-3-oxobenzisothiazolin-2-ylmethyl 1,1-di-oxide phosphate (diethyl 4,4-dimethyl-4,5,6,7-tetrahydro-2-saccharinylmethyl phosphate) as a colorless oil.

Example 25

- Diisopropyl 6-ethoxy-4-isopropyl-2-saccharinylmethyl phosphate (Example 19) can also be prepared by a procedure similar to that of Example 22, i.e, by reacting diisopropyl 6-hydroxy-4-isopropyl-2-saccharinylmethyl



phosphate with triphenylphosphine, ethanol and diethyl azodicarboxylate.

Following the procedure of Example 22 but substituting for glycerol dimethylketal the appropriate alcohol there can be prepared the diisopropyl 4-R₁-R₂-R₃-2-saccharinylmethyl phosphates in TABLE 2.

TABLE 2

Example	R ₁	R ₂	R ₃
26	CH(CH ₃) ₂	6-OCH ₂ (CH ₃) ₂	H
27	CH(CH ₃) ₂	6-(OCH ₂ CH ₂) ₂ OCH ₃	H
28	CH(CH ₃) ₂	6-OCH ₂ COOCH ₃	H
29	CH(CH ₃) ₂	6-OCH ₂ CH ₂ (OCH ₃)CH ₂ OCH ₃	H
30	CH(CH ₃) ₂	6-O-cyclobutyl	H
31	CH(CH ₃) ₂	6-OP(O)(OCH ₂ CH ₃) ₂	H
32	CH(CH ₃) ₂	6-OCH ₂ CH ₂ -1-morpholinyl	H

The 2,3-dimethoxy-1-propanol which is used in the preparation of Example 29 was synthesized as follows:
A solution of 10.0 g (0.055 mol) DL-α-O-benzylglycerol in a little THF was added to a suspension of 15.38 g (0.137 mol) potassium tert-butoxide in 300 ml THF. The mixture was stirred for 1 hr at RT and 18.72 g (0.132 mol) of iodomethane was added. A white solid immediately separated. The reaction was stirred for 10 hr at RT, cooled, carefully diluted with sodium chloride solution and extracted with ether. The organic layer was washed with water, 5% HCl, water and saturated NaCl and dried. The solvent was removed and the residue was purified by flash chromatography to give 1-benzyloxy-2,3-dimethoxypropane, 9.16 g (79%), as an oil.

A solution of 8.8 g (0.042 mol) of this material in 200 ml MeOH was hydrogenated using 1.1 g 10% Pd/C at



50 psi. The catalyst was removed by filtration and the solvent was evaporated under reduced pressure to give 4.4 g (87%) of 2,3-dimethoxy-1-propanol.

Example 33

5 By reacting diisopropyl 6-hydroxy-4-isopropyl-2-saccharinylmethyl phosphate (1 mol) in MDC, with trifluoromethanesulfonic anhydride (1.3 mol) in the presence of triethylamine (3 mol) at 0°C there can be obtained, after standard workup and purification, diisopropyl 4-isopropyl-6-trifluoromethanesulfonyloxy-2-saccharinylmethyl phosphate.
10

Example 34

By reacting in a nitrogen atmosphere the product of Example 33 (1 mol), in p-dioxane, with 1-methyl-2-trimethylstannyl-pyrrole (1.6 mol) in the presence of tetrakis (triphenylphosphine) palladium (O) (0.02 mol), lithium chloride (3.1 mol) and 2,6-di-tert-butyl-4-methylphenol (0.1 mol) under reflux, there can be obtained, after standard workup and purification, diisopropyl 4-isopropyl-6-[2-(1-methylpyrrolyl)]-2-saccharinylmethyl phosphate.
15
20

Example 35

By reacting the product of Example 33 (1 mol) in THF with 40% aqueous dimethylamine (4.4 mol) at RT, there can be obtained, after standard workup and purification, diisopropyl 6-dimethylamino-4-isopropyl-2-saccharinylmethyl phosphate.
25

Example 36

By reacting diisopropyl 6-hydroxy-4-isopropyl-2-saccharinylmethyl phosphate in toluene with di-(sec-butoxymethyl)methylamine at 80°C, there can be obtained, after standard workup and purification, phosphoric acid diisopropyl 4-isopropyl-8-methyl-2,3,7,8-tetrahydro-9H-1,3-oxazino-[6,5-g]-3-oxobenzisothiazol-2-ylmethyl 1,1-dioxide ester.
30



Example 37

By treating diisopropyl 6-(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy-4-isopropyl-2-saccharinylmethyl phosphate (Example 22) (1 mol) with p-toluenesulfonic acid monohydrate (0.8 mol) in methanol-chloroform at RT, there can be obtained, after standard workup and purification, diisopropyl 6-(2,3-dihydroxypropoxy)-4-isopropyl-2-saccharinylmethyl phosphate.

Example 38

By reacting diisopropyl 6-hydroxy-4-isopropyl-2-saccharinylmethyl phosphate (1 mol) in acetone with tert-butyl bromoacetate (3.4 mmol) in the presence of anhydrous potassium carbonate (1.96 mol) at RT, there can be obtained, after standard workup and purification, diisopropyl 6-(2-tert-butoxy-2-oxoethoxy)-4-isopropyl-2-saccharinylmethyl phosphate.

Example 39

By substituting benzyl bromoacetate for tert-butyl bromoacetate in Example 38, there can be obtained diisopropyl 6-(2-benzyloxy-2-oxoethoxy)-4-isopropyl-2-saccharinylmethyl phosphate which can be converted by hydrogenation over palladium-on-carbon to diisopropyl 6-carboxymethoxy-4-isopropyl-2-saccharinylmethyl phosphate.

Example 40

Following the procedure of Example 3 but substituting 2-chloromethyl-4-hydroxysaccharin for 2-chloromethyl-4-isopropyl-6-methoxysaccharin there can be obtained dibenzyl 4-hydroxy-2-saccharinylmethyl phosphate.

Example 41

Following a procedure similar to that of Example 22, dibenzyl 4-hydroxy-2-saccharinylmethyl phosphate can be reacted with diethyl diazocarboxylate, triphenylphosphine and benzyl alcohol to give dibenzyl 4-benzyloxy-2-saccharinylmethyl phosphate.



Following a procedure similar to that described in Example 3, each of the 4-R₁-R₂-R₃-2-chloromethylsaccharins of Preparations 1 to 86, the 4-R₄-4-R₅-6-R₆-chloromethyl-4,5,6,7-tetrahydrosaccharins of Preparations 87, 88, 92E to 94E, 95 and 96 and the 4,7-methano-, 4,7-dimethylmethano- and 4,7-ethano-4,5,6,7-tetrahydrosaccharins of Preparations 89 to 91 respectively can be reacted with each of the phosphoric acid di-esters, phosphonic acid mono-esters and phosphinic acids of formula III listed in TABLES 3 and 4 to give the corresponding compounds of formulas I, II and IIA respectively.









TABLE 3

Formula III		
m / n	A	B
1 / 1	$\begin{array}{c} \text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2 \\ \\ \text{CH}_2\text{CH}_3 \end{array}$	$\begin{array}{c} \text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2 \\ \\ \text{CH}_2\text{CH}_3 \end{array}$
1 / 1	CH ₂ (CH ₂) ₈ CH ₃	CH ₂ (CH ₂) ₈ CH ₃
1 / 1	C ₆ H ₄ -4-(OCH ₃)	C ₆ H ₄ -4-(OCH ₃)
0 / 1	Ph	CH ₂ Ph
0 / 1	Ph	2-pyridinyl
0 / 1	CH ₂ CH(CH ₃) ₂	CH ₃
0 / 1	Ph	CH ₃
0 / 1	CH ₃	CH ₃
0 / 1	CH ₃	CH ₂ CH ₃
0 / 0	Ph	CH ₂ CH ₃
0 / 0	Ph	CH ₂ (CH ₃) ₂
0 / 0	Ph	CH ₂ Ph
0 / 0	CH ₃	CH ₃
0 / 0	CH ₂ CH ₃	CH ₂ CH ₃
0 / 0	CH ₃ (CH ₂) ₈ CH ₂	CH ₃ (CH ₂) ₈ CH ₂



TABLE 4

Formula III: m=n=1: A and B taken together




This Sheet Has Been Replaced



The methylphosphonic acid mono(2-methylpropyl) ester and methylphosphonic acid monophenyl ester in TABLE 3 can be prepared from methylphosphonochloridic acid (2-methylpropyl) ester and methylphosphonochloridic acid phenyl ester respectively by hydrolysis.

The ethylphenylphosphinic acid and isopropylphenylphosphinic acid in TABLE 3 can be prepared by conventional O-alkyl cleavage from the corresponding methyl esters, e.g., by reaction with trimethylsilyl bromide $[(CH_3)_3SiBr]$ and hydrolysis of the trimethylsilyl ester so formed.

Conventional hydrolysis under acidic conditions of the compound resulting in each case from reaction of the chloromethyl compounds of Preparations 1 to 96 with the compound of formula III wherein A and B together represent



wherein R_9 and R_{10} together represent isopropylidene (TABLE 4) affords the corresponding compound wherein R_9 and R_{10} each is hydrogen.

Measurement of the inhibition constant, K_i , of a HLE-inhibitor complex has been described for truly reversible inhibition constants usually concerning competitive inhibitors [Cha, Biochem. Pharmacol., 24, 2177-2185 (1975)]. The compounds of the present invention, however, do not form truly reversible inhibitor complexes but are consumed by the enzyme to some extent. Thus, instead of measuring a K_i , a K_i^* is calculated which is defined as the ratio of the k_{off}/k_{on} , the rate of reactivation of the enzyme to the rate of inactivation of the enzyme. The values of k_{off} and k_{on} are measured and K_i^* is then calculated.



The rate of inactivation, k_{on} , of enzymatic activity was determined for the compounds tested by measuring the enzyme activity of an aliquot of the respective enzyme as a function of time after addition of the test compound. By plotting the log of the enzyme activity against time, an observed rate of inactivation, k_{obs} , is obtained which can be represented as $k_{obs} = \ln 2/t_{1/2}$ where $t_{1/2}$ is the time required for the enzyme activity to drop by 50%. The rate of inactivation is then equal to

$$k_{on} = \frac{k_{obs}}{[I]}$$

where $[I]$ is the concentration of the inhibiting compound.


The reactivation constant, k_{off} , is similarly determined, and the inhibition constant, K_i^* , is then calculated as

$$K_i^* = k_{off}/k_{on}$$

The K_i^* values determined for the compounds of Examples 1 to 22 were in the range of from 0.035 to 100 nM.

The compound of Example 13 had a K_i^* of 0.035.

This Sheet Has Been Replaced




CLAIMS


5

1. A compound having the formula

10



This Sheet Has Been Replaced



wherein:

R_1 is hydrogen, halogen, lower-alkyl, perfluoro-
15 lower-alkyl, perchloro-lower-alkyl, lower-alkenyl, lower-alkynyl, cyano, amino, lower-alkylamino, di-lower-alkylamino, carboxamido, lower-alkoxy, benzyloxy, hydroxy, lower-alkoxy-carbonyl or phenyl;

R_2 and R_3 are independently hydrogen or a
20 substituent in any of the available 5-, 6- or 7-positions selected from the group consisting of halogen, cyano, nitro, $N=B$, 1-lower-alkyl-2-pyrrolyl, lower-alkylsulfonylamino, polyfluoro-lower-alkyl-sulfonylamino, polychloro-lower-alkylsulfonylamino, amino-sulfonyl, lower-alkyl, polyfluoro-
25 lower-alkyl, polychloro-lower-alkyl, cycloalkyl, lower-alkoxy, hydroxy, carboxy, carboxamido, hydroxy-lower-alkyl, formyl, aminomethyl, polyfluoro-lower-alkylsulfonyl, polychloro-lower-alkylsulfonyl, lower-alkylsulfonylaminosulfonyl, lower-alkoxycarbonyl-lower-alkylamino, lower-alkylcarbonylamino,
30 lower-alkoxy-poly-lower-alkyleneoxy, cycloalkyloxy, hydroxy-lower-alkoxy, polyhydroxyalkoxy, or acetal or ketal thereof, polyalkoxyalkoxy, $(\text{lower-alkoxy})_2P(O)O-$, $-SR$, $-SOR$, $-SO_2R$, $-OCOR$, $-O-(C_{1-10}\text{-alkylene})-COOR$, $-O-(C_{1-10}\text{-alkylene})-COOH$ and $-O-(C_{2-10}\text{-alkylene})-N=B$, where R is lower-alkyl,
35 phenyl, benzyl or naphthyl, or phenyl or naphthyl substituted by from one to two substituents selected from lower-alkyl,





lower-alkoxy or halogen, and -N=B in each instance is amino,
lower-alkylamino, di-lower-alkylamino, 1-azetidiny, 1-pyrroldinyl,
1-piperidinyl, 4-morpholinyl, 1-piperazinyl, 4-lower-alkyl-1-piperazinyl,
4-benzyl-1-piperazinyl, 1-imidazolyl or (carboxy-lower-alkyl)amino;

or R₂ and R₃ together represent a 3-atom or 4-atom unsubstituted or methylated saturated bridge bridging the carbon atoms at the 5,6 or 6,7 positions, wherein the atoms of the bridge consist of one or two carbon atoms and two of the same or different heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;

m and n are independently 0 or 1;


when m and n are 1, A and B are independently hydrogen, lower-alkyl, phenyl, lower-alkoxyphenyl or benzyl, or, taken together, represent:



30

where R₇ and R₈ are independently hydrogen or chlorine, R₉ and R₁₀ each is hydrogen or together represent isopropylidene, p is 0 or 1 and r is 2, 3 or 4;

when m is 1 and n is 0, A and B are independently lower-alkyl, phenyl, benzyl or 2-pyridinyl; and



when m and n are 0, A and B are independently lower-alkyl, phenyl or lower-alkoxyphenyl; or acid-addition salts of basic members thereof or base-addition salts of acidic members thereof.

2. A compound as claimed in Claim 1

wherein:

R₁ is hydrogen, lower-alkyl or lower-alkoxy;

10 R₂ is lower-alkoxy, polyalkoxyalkoxy, lower-alkoxy-poly-lower-alkyleneoxy or polyhydroxyalkoxy, or ketal or acetal thereof;

R₃ is hydrogen or lower-alkoxy;

m and n both are 0 or 1;

15 when m and n are 1, A and B are independently hydrogen, lower-alkyl, phenyl, lower-alkoxyphenyl or benzyl; and

when m and n are 0, A and B are independently lower-alkyl, phenyl or lower-alkoxyphenyl.

20 3. A compound as claimed in Claim 1

wherein:

R₁ is hydrogen, lower-alkyl or lower-alkoxy;

R₂ is hydrogen, hydroxy, lower-alkoxy or polyhydroxyalkoxy, or ketal or acetal thereof;

25 R₃ is hydrogen;

m and n both are 0 or 1;


when m and n are 1, A and B are independently hydrogen, lower-alkyl, phenyl, lower-alkoxyphenyl or benzyl; and

30 when m and n are 0, A and B are independently lower-alkyl, phenyl or lower-alkoxyphenyl.

4. A compound as claimed in Claim 3 wherein A and B are identical.

35

This Sheet Has Been Replaced



5. A compound as claimed in Claim 4 selected from the group consisting of the compounds wherein R_3 in each case is hydrogen and R_1 , R_2 , m , n , A and B are as follows:

	R_1	R_2	$m=n=$	$A=B=$
	H	H	1	$(CH_2)_3CH_3$
	OCH_2CH_3	H	1	CH_2CH_3
10	$CH(CH_3)_2$	6- OCH_3	1	CH_2Ph
	H	H	1	CH_2Ph
	H	H	1	CH_3
	H	H	1	CH_2CH_3
	H	H	1	Ph
15	H	H	0	Ph
	H	H	0	$C_6H_4-4-(OCH_3)$
	$CH(CH_3)_2$	H	1	CH_2CH_3
	OCH_3	6- OCH_3	1	CH_2CH_3
	$CH(CH_3)(CH_2CH_3)$	H	1	CH_2CH_3
20	$CH(CH_3)_2$	6- OCH_3	1	CH_2CH_3
	$CH(CH_3)_2$	H	0	Ph
	$CH(CH_3)_2$	6- OCH_3	0	Ph
	$CH(CH_3)_2$	H	1	CH_2Ph
	$CH(CH_3)_2$	6-OH	1	CH_2CH_3
25	$CH(CH_3)_2$	6- OCH_3	1	$CH(CH_3)_2$
	$CH(CH_3)_2$	6- OCH_2CH_3	1	$CH(CH_3)_2$
	$CH(CH_3)_2$	6- OCH_3	0	$(CH_2)_3CH_3$
	$CH(CH_3)_2$	6-OH	1	$CH(CH_3)_2$
	H	H	1	H
30	$CH(CH_3)_2$	6- $OCH_2-CH-CH_2$ $\begin{array}{c} \quad \\ O \quad O \\ \quad \\ CH_3 \quad C \quad CH_3 \end{array}$	1	$CH(CH_3)_2$

35




This Sheet Has Been Replaced



6. A compound having the formula:

5



This Sheet Has Been Replaced

10


wherein:

R_4 is hydrogen, lower-alkyl or phenyl;
 R_5 is hydrogen or primary lower-alkyl;
 or R_4 and R_5 , taken together, represent ethylene;
 R_6 is hydrogen or lower-alkoxy;
 m and n are independently 0 or 1;


15

when m and n are 1, A and B are independently
 hydrogen, lower-alkyl, phenyl, lower-alkoxyphenyl or benzyl,
 or, taken together, represent:


20



25



or



30

where R_7 and R_8 are independently hydrogen or chlorine,
 R_9 and R_{10} each is hydrogen or together represent
 isopropylidene, p is 0 or 1 and r is 2, 3 or 4;

35




when m is 1 and n is 0, A and B are independently lower-alkyl, phenyl, benzyl or 2-pyridinyl; and

5 when m and n are 0, A and B are independently lower-alkyl, phenyl or lower-alkoxyphenyl; or acid-addition salts of basic members or base-addition salts of acidic members thereof.

10 7. A compound as claimed in Claim 6 wherein:

R_4 is hydrogen or lower-alkyl; and
 R_5 is hydrogen or primary lower-alkyl;
or R_4 and R_5 , taken together, represent ethylene.

15 8. A compound having the formula:



wherein:

C is methylene, ethylene or dimethylmethylene;

m and n are independently 0 or 1;

25 when m and n are 1, A and B are independently hydrogen, lower-alkyl, phenyl, lower-alkoxyphenyl or benzyl, or, taken together, represent:


30

This Sheet Has Been Replaced



35





15

where R₇ and R₈ are independently hydrogen or chlorine, R₉ and R₁₀ each is hydrogen or together represent isopropylidene, p is 0 or 1 and r is 2, 3 or 4;

20 when m is 1 and n is 0, A and B are independently lower-alkyl, phenyl, benzyl or 2-pyridinyl; and

when m and n are 0, A and B are independently lower-alkyl, phenyl or lower-alkoxyphenyl; or acid-addition salts of basic members or base-addition salts of acidic

25 members thereof.


9. A compound as claimed in Claim 8 wherein C is methylene.

30 10. A composition for the treatment of degenerative diseases which comprises a pharmaceutical carrier and an effective proteolytic enzyme inhibiting amount of a compound as claimed in Claim 1.

35 11. A composition for the treatment of degenerative diseases which comprises a pharmaceutical carrier and an effective proteolytic enzyme inhibiting amount of a compound as claimed in Claim 6.

12. A composition for the treatment of degenerative diseases which comprises a pharmaceutical

This Sheet Has Been Replaced



carrier and an effective proteolytic enzyme inhibiting amount of a compound as claimed in Claim 8.

5 13. The use of a compound as claimed in Claim 1 for the preparation of a medicament for the treatment of a degenerative disease in a patient in need of such treatment.

10 14. The use of a compound as claimed in Claim 6 for the preparation of a medicament for the treatment of a degenerative disease in a patient in need of such treatment.

 15. The use of a compound as claimed in Claim 8 for the preparation of a medicament for the treatment of a degenerative disease in a patient in need of such treatment.

15

20

25

30

35

This Sheet Has Been Replaced

